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ABSTRACT 
Type 2 Diabetes Mellitus (T2DM) is a heterogeneous metabolic disease characterized by 
elevated blood glucose levels that has reached pandemic proportions. Genome-wide 
association studies have linked T2DM to the function of the insulin-producing pancreatic β-
cell residing in the micro-organ islet of Langerhans. An individual´s risk to develop T2DM 
depends on genetic predisposition and environmental factors, e.g. life style. Central for disease 
development is the interplay between insulin resistance in insulin target tissues like muscle, 
liver and fat and deficient β-cell insulin secretion. Since the β-cell is an insulin target itself, β-
cell insulin resistance can contribute to β-cell dysfunction and the development of T2DM. This 
was shown in several genetic (knockout) mouse models, however the dynamics of β-cell insulin 
resistance and its relevance in a diet-induced context has so far not been explored. Furthermore 
the consequences of diet-induced β-cell insulin resistance for β-cell function remain to be 
understood. The difficulty to study β-cell insulin resistance in vivo has partly been due to the 
lack of a technique to monitor β-cell insulin resistance non-invasively and longitudinally in the 
living organism.  
In my thesis I employed the anterior chamber of the eye of mice as a transplantation site for 
biosensor-expressing reporter islets and the cornea as a natural body window to monitor β-cell 
insulin resistance non-invasively and longitudinally by microscopic imaging. The β-cell insulin 
resistance biosensor is based on GFP-labeled FoxO1, that changes its intracellular localization 
from cytoplasmic (insulin responsive) to nuclear (insulin resistant). With this technique we 
investigated β-cell insulin resistance dynamics in ob/ob and NZO mice and demonstrated that 
β-cell insulin resistance dynamics vary in animal models of insulin resistance and obesity. 
Furthermore, we showed that β-cell insulin resistance developed in the presence of whole-body 
insulin resistance, impaired glucose tolerance and increased body weight, but independently 
from liver insulin resistance. To study the relevance of β-cell insulin resistance in diet-induced 
T2DM development, we treated diabetes-prone male C57BL/6J mice with different 
combinations of solid high fat diet and drinking water containing either sucrose or fructose. 
Employing our new monitoring technique we showed that only mice that were fed a High-Fat-
High-Sucrose-Diet developed β-cell insulin resistance. This demonstrated the importance of β-
cell insulin resistance in a model of diet-induced obesity and insulin resistance and highlighted 
the importance of diet composition for the development of T2DM. The β-cell insulin resistance 
was accompanied by a decreased functional β-cell mass and impaired insulin secretion 
downstream of glucose-stimulated Ca2+ influx, due to a reduction of syntaxin-1A. We were 
also able to show that β-cell insulin resistance in one insulin signaling cascade can re-route the 
insulin signal, thus allowing the co-existence of reduced and increased insulin response in the 
same cell.  
In conclusion, my in vivo studies of diet-induced β-cell insulin resistance and its consequences 
on β-cell function and survival contribute to better understanding of the development of T2DM.  
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1 INTRODUCTION 
 
Type 2 Diabetes Mellitus (T2DM) is a heterogeneous disease that has reached pandemic 
proportions during the last decades, affecting around 9% of the adult population worldwide. 
It is characterized by elevated blood glucose levels due to relative insulin deficiency as the 
result of impaired insulin secretion and/or utilization. Consequences of chronically elevated 
blood glucose levels are manifold and include amongst others kidney failure, blindness as 
well as leg amputation and contribute to premature death. Both the genetic background and 
environmental factors have been identified as risk factors leading to huge variety of possible 
underlying mechanisms for disease development. Especially the increased intake of fast 
food, consisting of high amounts of sugar and fat, in combination with a sedentary life style, 
is believed to contribute to the rise in T2DM cases1,2,3.  
Genome-wide association studies have linked pancreatic β-cell function to T2DM4. The 
pancreatic β-cell within the micro-organ islet of Langerhans secretes insulin upon glucose 
stimulation. The interplay of insulin resistance in insulin target tissues, like muscle, liver 
and fat, with β-cell insulin secretion deficiency is seen as central for the disease 
development5. It has been shown that the β-cell is not only the site of insulin production, 
but also an insulin target tissue, where insulin signaling takes place6. Consequently also the 
β-cell can develop insulin resistance that potentially contributes to β-cell dysfunction and 
subsequently to the development of T2DM. Several genetic (knockout) mouse models have 
shown that a failure in β-cell insulin signaling due to the absence of a member of the insulin 
signaling cascade can lead to the development of β-cell insulin resistance7–12. The relevance 
of β-cell insulin resistance in a diet-induced context has so far not been investigated. One 
reason is the accessibility of β-cells in the pancreas for monitoring techniques. While it is 
possible to measure glucose and insulin tolerance non-invasively by tolerance tests, until 
now no method has been available to non-invasively monitor β-cell insulin sensitivity 
longitudinally in vivo.  
A few years ago our group developed a technique to longitudinally and non-invasively 
monitor islets of Langerhans in mice13,14. There, pancreatic islets were transplanted to the 
anterior chamber of the eye (ACE) of mice, where they have been shown to become fully 
vascularized and innervated. Employing the cornea as a natural body window allowed to 
follow engrafted islets over time at cellular resolution by employing microscopic imaging. 
Since it has been shown that these islets report on the function of islets in the pancreas15, 
the in vivo imaging platform gives the possibility to longitudinally study β-cells in islets of 
Langerhans in vivo. For investigation of specific functions and aspects, genetically encoded 
fluorescent biosensors can be used16–18.  
The aim of the present work was to develop and validate a method to study dynamics of β-
cell insulin resistance in vivo, to explore the relevance of β-cell insulin resistance in the 
context of diet-induced T2DM development and furthermore to start to investigate the 
consequences of β-cell insulin resistance for β-cell function.   
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2 BACKGROUND 
 
2.1 Diabetes mellitus 
2.1.1 Definition, characteristics and epidemiology of diabetes mellitus 
Diabetes mellitus is a heterogeneous metabolic disease that is characterized by increased 
blood glucose levels. In humans one of the following three different criteria is used for 
diagnosis: 1) fasting plasma glucose level of ≥ 7 mmol/l; 2) plasma glucose 2 hours after 
glucose stimulation is ≥ 11.1 mmol/l; 3) HbA1c ≥ 6.5%. The increased levels of blood 
glucose can be due to the failure or dysfunction of one or more processes involved in glucose 
homeostasis1.  
Already in 1906 a connection was seen between the proper function of pancreatic islets of 
Langerhans and the ability of the organism to maintain normal glucose concentration19. The 
islets of Langerhans were discovered by Paul Langerhans in 1869 and are situated in the 
pancreas there forming the endocrine part. It is a highly vascularized and innervated micro-
organ consisting of different cell types: Non-endocrine dendritic, neuronal, Schwann and 
endothelial cells, pericytes, and macrophages as well as endocrine cells including the insulin 
producing β-cell, the glucagon producing α-cell, somatostatin releasing δ-cells as well as 
pancreatic polypeptide producing PP/γ-cells and ghrelin producing ε-cells. All endocrine 
islet cells release their hormones in response to multiple signals. The islet has a diameter of 
50 to 280 µm and a healthy human has ca. 1 million islets, while a mouse has 3000-5000 
islets. The hormone insulin is responsible for a lowering of blood glucose levels and 
produced by the β-cell20. Genome wide association studies have linked genes associated 
with diabetes to β-cell function4. In general insulin acts on various target tissues where it 
fulfills different functions all aiming to keep blood glucose levels in a physiological range20. 
Consequently a failure in one of these processes can lead to impaired glucose homeostasis 
and finally to diabetes.  
Uncontrolled diabetes can lead to many different late complications such as neuropathy, 
nephropathy, micro- and macroangiopathy leading to amongst other things myocardial 
infarction, stroke, kidney failure, vision loss, leg amputation and it is one leading cause for 
premature death. 422 million adults were estimated to live with diabetes in 2014 and it was 
responsible for 1.5 million deaths in 2012 worldwide. Additionally 2.2 million deaths were 
reported to be related to higher-than-optimal blood-glucose levels. It is expected that these 
numbers will rise during the next decades1,2.  
2.1.2 Types of diabetes mellitus 
Diabetes is currently divided into different subgroups and the categorization is based on the 
time and cause of onset. Type I Diabetes Mellitus (T1DM) is characterized by β-cell loss, 
resulting in absolute insulin deficiency and without any insulin treatment these patients 
cannot survive. The loss of β-cells is thought to be provoked by autoimmune disruption, but 
the exact cause for the disease is unknown and still under investigation. Regional differences 
in prevalence are seen, but also genetics and other environmental influences are risk factors 
for T1DM. Mostly children and adolescents are affected by T1DM1,2. Latent Autoimmune 
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Diabetes in Adults (LADA) is a form of diabetes that is caused by autoimmune disease, but 
it progresses slower than T1DM and is therefore often diagnosed in adults21.  
The present work focuses on T2DM. T2DM encompasses currently around 90% of diabetes 
cases worldwide. In contrast to T1DM, β-cells still remain and produce insulin in T2DM, 
but the amounts of secreted insulin are not sufficient to keep the blood glucose level within 
physiological range. This is most often due to insulin resistance of insulin target tissues, 
defined as the inability to use insulin effectively22. In response to insulin resistance of liver, 
muscle and fat, β-cells initially increase their insulin secretion. In humans a fasting plasma 
insulin concentration higher than 60 pmol/l23 is considered as insulin resistance. As the 
disease progresses insulin secretion by the β-cells becomes defective and diabetes develops. 
Consequently, insulin resistance of the classical insulin target tissues in combination with 
impaired insulin secretion by the β-cell causes T2DM5. Since disease symptoms are less 
pronounced in T2DM, the disease can remain undiagnosed for years1,2. In general, 
underlying failures in insulin tolerance and secretion can be multifactorial and lead to 
differences in the disease characteristics of the individual level. New classifications to 
stratify patient groups with diabetes are currently under discussion24.  
Another type of diabetes mellitus is gestational diabetes only occurring during pregnancy 
when any degree of hyperglycemia is recognized for the first time25.  
2.1.3 Risk factors and prevention of Type 2 Diabetes Mellitus 
Even if the underlying disease mechanisms cannot be addressed for each patient, risk factors 
for T2DM have been found and are used as a good starting point for diabetes prevention. 
The interplay between genetics and metabolic risk factors contributes to the individual risk 
to develop T2DM26. Family history of diabetes and ethnicity are risk factors that cannot be 
influenced, but it has been shown that a healthy life style can delay or prevent the onset of 
diabetes27,28. Healthy life style includes physical activity, avoidance of smoking and high 
consumption of alcohol. But highest emphasis is on the prevention of diabetes by adequate 
food and beverage consumption, avoiding high intake of saturated fatty acids and sugar, but 
encouraging the intake of fresh fruit, vegetables and fibres1,2. Here it has to be noted that 
the frequently used body mass index (BMI) cannot exclusively be used to measure 
someone’s risk for the development of diabetes. One should consider additional 
measurements of several other parameters like the amount of visceral and subcutaneous fat, 
fitness and insulin sensitivity29.   
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2.2 The pancreatic β-cell 
The β-cell within the micro-organ islet of Langerhans is the site of insulin production, 
release and also of insulin signaling. Nerve stimulation, intra islet cell-cell communication, 
and humoral factors (hormones, vitamins, nutrients and more) play an important role in the 
regulation of β-cell function. Also paracrine signals from other pancreatic endocrine cell 
types influence the β-cell. Among others glucagon released from pancreatic α-cells 
stimulates insulin secretion and somatostatin secreted by pancreatic δ-cells suppresses 
insulin release. It has also been shown that the β-cell is an insulin target tissue. That was 
unexpected and controversially discussed, because the β-cell is thought to be permanently 
exposed to insulin. As an autocrine signal, insulin influences β-cell functions such as 
maintenance of β-cell mass, insulin biosynthesis and secretion in a short- and long-term 
dependent manner via insulin signaling through different pathways downstream of the 
insulin receptors. Variety of insulin signaling downstream of the insulin receptors is 
achieved by interaction of insulin receptors with different proteins involving different 
protein binding motifs within the receptor β-chains6,30.  
2.2.1 Insulin- “stimulus-secretion coupling”  
Glucose is taken up by the β-cell via the insulin-independent Glucose transporter 2 (GLUT2) 
(mouse)/ Glucose transporter 1 (GLUT1) (human). Subsequent to phosphorylation by 
glucokinase, glucose is metabolized in glycolysis and further in the Krebs cycle. This results 
in a change in the Adenosine tri-phosphate (ATP)/ Adenosine di-phosphate (ADP) ratio in 
the cytoplasm and the closing of ATP/ADP-sensitive potassium channels. Since potassium 
ions no longer leave the cell, membrane depolarization occurs leading to opening of voltage-
dependent L-type Ca2+-channels. Ca2+ entering the cell promotes insulin exocytosis31(Fig. 
2.1).   
2.2.2 Insulin signaling via insulin receptor-A and -B 
Two different insulin receptor (IR) isoforms have been identified: Insulin receptor-A and -
B (IR-A and IR-B). They differ in 12 amino acids in the C-terminus of the α-chain of the 
receptor, a result of alternative splicing of exon 11 of the IR transcript32. IR-A lacks exon 
1133 in contrast to IR-B that contains it34. Downstream of IR-A insulin regulates the 
expression of its own gene via a signaling cascade in a short-term manner. Insulin binding 
to the IR leads to its autophosphorylation by tyrosine kinase activity. The insulin receptor 
substrate 2 (IRS-2) recognizes the NPEY-motif of IR-A and mediates the receptor tyrosine 
kinase activity to Class IA Phosphatidylinositol 3-Kinase (PI3K Ia) and p70s6k as well as 
to Ca2+/calmodulin-dependent protein kinase II (CaMKII) activities35–37. Downstream of 
IR-B two different pathways have been identified. Class IIA Phosphatidylinositol 3-Kinase 
(PI3K-C2α) recognizes the NPEY-motif of the receptor and mediates the signaling to 
Phosphoinositide-dependent kinase-1 (PDK1) and PKB/Akt which regulates glucokinase 
gene expression (Fig. 2.1). This signaling cascade is known as metabolic pathway of insulin 
signaling.  
In the context of mitogenic effects on the other hand PI3K Ia binds to the YTHM-domain 
of the β-chain of the IR and is necessary for subsequent recruitment of p52-Shc to IR-B. 
Shc binds to the c-terminal YTHM-motif of the IR-B and the complex of IR-B/Shc is 
internalized into clathrin-coated vesicles. It has been shown that further Shc signaling 
derives from early endosomes, involving signaling via Grb2/Sos/Ras/Raf/MEK1/ERK1/2 
leading to transcription of c-fos. This signaling cascade is known as mitogenic pathway of 
insulin signaling and triggers proliferation37 (Fig. 2.1).   
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Figure 2.1.: The pancreatic β-cell 
Increased glucose uptake and metabolism stimulates insulin secretion. Secreted insulin influences β-cell 
function through different pathways downstream of IR-A and -B in an autocrine manner.   
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2.2.3 β-cell insulin resistance 
First evidence for the existence of β-cell insulin resistance and its relevance to glucose 
homeostasis, adequate insulin secretion and β-cell mass in vivo, came from β-cell-targeted 
manipulation of candidate genes playing a role in β-cell insulin signaling. A β-cell specific 
knockout (KO) of the IRs in βIRKO mice resulted in impaired glucose tolerance and reduced 
insulin secretion7. This mouse model demonstrated that a failure in β-cell insulin signaling, 
i.e. β-cell insulin resistance, can contribute to the development of T2DM. This was also 
shown in β-cell specific KO models of other members in the insulin signaling cascade, such 
as IRS-210, PI3K12 and Akt38, all displaying impairment of glucose-stimulated insulin 
secretion. Deeper analysis of the underlying molecular consequences of altered insulin 
signaling in KO mouse models gave further insights into the importance of β-cell insulin 
resistance/insulin sensitivity.  
The lack of IRS-2 provoked a decrease in β-cell mass due to decreased proliferation and 
attenuated Ca2+ fluxes in response to glucose. Gene expression and protein analysis of β-
cells from IRS-2 KO mice revealed a decrease in GLUT2, but maintained levels of the β-
cell master regulator pancreatic and duodenal homeobox 1 (Pdx1) and of glucokinase10. This 
mouse model demonstrated the importance of IRS-2 and intact insulin signaling for 
maintenance of β-cell mass and regulation of insulin secretion. PI3K Ia deletion12 affected 
downstream events of insulin signaling, resulting in nuclear localization and activation of 
the transcription factor forkhead box protein O1 (FoxO1). Here, both increased apoptosis 
and proliferation of β-cells were observed. A reduction in exocytotic events in combination 
with normal levels of cytosolic free Ca2+ ([Ca2+]i) suggested a defect downstream of the 
Ca2+ influx machinery. Gene expression analysis revealed maintained glucokinase levels, 
but a reduction in GLUT2 and Pdx1, going hand in hand with the nuclear localization of 
FoxO1. Furthermore a decrease in expression of soluble N-ethylmaleimide attachment 
receptor (SNARE) complex proteins was observed12. Reduced Akt activity in β-cells38 led 
to impaired insulin secretion due to a defect in exocytosis independent from Ca2+ influx. β-
cell mass was unaffected in these mice. The importance of the genetic background on the 
phenotypical outcome in mice was demonstrated when the same KO was introduced into 
mice with different genetic backgrounds resulting in great phenotypical variation39. 
Especially C57BL/6J (B6) mice were shown to be more prone to develop diabetes40. The 
observed effects in KO mice were similar in general (e.g. resulting in reduced glucose 
stimulated insulin secretion), but also different in detail, emphasizing the requirement to 
specify insulin resistance due to the complexity of the huge network of different insulin 
signaling pathways giving the possibility to cause insulin resistance in many different ways.  
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2.2.4 Forkhead box protein O1 (FoxO1) 
FoxO1 is a transcription factor and the most abundant member of the family of Forkhead 
transcription factors regulating several different cell processes like proliferation, 
differentiation and survival in a broad spectrum of cell types41,42. It is evolutionary 
conserved and has important functions in the β-cell. FoxO1 phosphorylation and the 
resulting subcellular localization is regulated by glucose through IR signaling via the 
PI3K/Akt pathway43 and by the c-Jun-N-terminal kinase (JNK) pathway44. Under normal, 
insulin responsive, conditions, FoxO1 is phosphorylated by Akt leading to its cytoplasmic 
localization. In case of failure in insulin signaling, i.e. insulin resistance, FoxO1 is no longer 
phosphorylated by Akt resulting in its translocation to the nucleus where it binds to its target 
genes promoting their expression45. Also oxidative stress can provoke FoxO1 nuclear 
localization by either acetylation by Cbp/p300-interacting trans-activator 146 or 
phosphorylation by JNK, at phosphorylation sites distinct from those of Akt44.  
Important FoxO1 target genes in the β-cell are the transcription factors MafA, NeuroD and 
Pdx1. MafA and NeuroD are important transcription factors in insulin expression, but also 
for β-cell differentiation during embryogenesis46,47. Pdx1 is one of the master transcription 
factors of the β-cell, regulating the expression of several β-cell genes, including GLUT248. 
FoxO1 as a negative regulator of Pdx1 shows an opposite nuclear localization pattern49.  
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2.3 The in vivo imaging platform 
The ACE has been used as a transplantation site since the 19th century50. It is an immune 
privileged site allowing the proper survival of the transplant and the transparency of the 
cornea makes it a natural body window. Beside others, pancreatic tissue was transplanted to 
the ACE for morphological studies51. In 2008 the ACE was reported for the first time as a 
transplantation site for in vivo imaging of pancreatic islets of Langerhans13,14. For this, donor 
pancreatic islets are isolated, e.g. by collagenase digestion and subsequent handpicking (Fig. 
2.2). Prior to transplantation the islets can be transduced with an adenovirus encoding a 
fluorescent biosensor (see 2.4). For transplantation, the recipient animal is anesthetized, a 
small hole is made into the cornea, and islets are gently injected and placed onto the iris. 
Normally syngeneic transplantations of age-matched islets are performed, but usage of 
immunocompromised mice allows also allogeneic or xenogeneic transplantation, the latter 
used for transplantation of human islets into mice52. After transplantation it takes 
approximately four weeks before the islets are fully vascularized14 and 3 months to be fully 
innervated in the ACE53,54. The pancreatic islets can be monitored in the anesthetized 
recipient by different microscopic techniques depending on the scientific question. Laser 
scanning confocal microscopy for instance allows high-resolution at the (sub-) cellular level.  
When the islets are vascularized the immune privilege of the anterior chamber is lost, and 
the islets are connected to the rest of the organism, allowing to draw conclusions from 
observations of islets in the ACE about conditions of the islets in the pancreas15. However, 
this has to be confirmed for every new biosensor.  
In general, two main approaches are used for islet transplantation into the ACE. Firstly, 
metabolic transplantations where the islets in the eye replace the endogenous islets when 
those are no longer able to maintain normoglycaemia, e.g. in diabetes. At least 75 islets are 
needed to replace the islets in the pancreas55. Secondly, transplanted, vascularized and 
innervated islets in the ACE can serve as reporter islets to longitudinally and non-invasively 
study in vivo islet morphology15, β-cell mass and function56. This allows cytolabeling in vivo 
to assess cell type and viability in situ. Furthermore this approach allows to test the effect 
of substances or diet interventions on the islets in the living animal as well as real-time 
tracking of immune cells57,58 
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Figure 2.2: The in vivo imaging platform 
Islets are isolated from recipients by collagenase digestion, followed by handpicking. One day after isolation 
islets can be transduced by incubation with adenovirus encoding a biosensor. Transduced islets are 
transplanted into the ACE one to three days after transduction by gently injection through a small hole in the 
cornea. From four weeks after transplantation islets in the eye can be monitored by microscopy. 
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2.4 Genetically encoded fluorescent biosensors (GEFBs) 
Many different imaging techniques have been employed to study and visualize biological 
processes and mechanisms in living cells59. Outstanding was the development of GEFBs, 
because their expression can be imaged in living cells without adding exogenous 
components. Prerequisite for the construction of GEFBs was the discovery of fluorescent 
proteins. In 1962 Shimomura was the first who extracted and described the green fluorescent 
protein (GFP) that he found in Aequorea jellyfish60. Cloning of the gene61 allowed 
expression and characterization of GFP in pro- and eukaryotic cells62. Chalfie and 
colleagues realized the potential and advantages of GFP for monitoring of cellular processes 
in living cells and suggested to use fluorescent proteins as a part of biosensors that report 
on cellular function. This was beside others done by R. Y. Tsien63 who also designed 
different GFP variants such as blue, yellow and cyan fluorescent proteins64. During the last 
20 years many fluorescent proteins have been developed (overview in 65) covering today a 
broad spectrum of colors. Each fluorescent protein has a defined excitation wavelength and 
a characteristic emission spectrum. This is of particular interest when combining different 
fluorescent proteins into a single GEFB. The combinatory use of fluorescent proteins 
requires that they differ in their excitation wavelength and/or emission profile or in the 
fluorescence life time for distinct identification.  
For construction of a GEFB the gene of interest and the cDNA of a fluorescent protein are 
fused and integrated into an expression construct that is delivered to the target cell by 
transfection/transduction16. In combination with high resolution imaging techniques such as 
confocal microscopy, subcellular localization as well as translocation of proteins can be 
monitored. Even co-localization of proteins can be analyzed when different proteins are 
fluorescently labeled66. Driving the expression of a fluorescent protein by a specific 
promoter allows semi-quantitative analysis of promoter activity35,67. Since the copy number 
of the biosensor can differ from cell to cell and consequently lead to differences in the 
amount of fluorescence, an internal control is fundamental for semi-quantitative analysis of 
fluorescence changes. GEFBs can also be used to investigate protein-protein interactions 
taking advantage of fluorescence/Förster resonance energy transfer (FRET), firstly 
described in 1948 by Theodor Förster68 (see also Material and Methods). In general, 
fluorescent proteins emit fluorescence either permanently or in response to a biochemical 
stimulus, e.g. pH or Ca2+. Protein interaction also can be studied by linking each part of a 
split-fluorescent protein to the proteins of interest, generating fluorescence only in case of 
protein-protein interaction due to protein complementation thus forming an intact 
fluorescent protein. Many more applications for the use of GEFBs have been described 
during the last years and are discussed in several reviews16–18,65.  
As mentioned above GEFBs have the advantage that they can be used long-term in living 
cells/organisms to monitor biological processes. Internal controls allow quantification and 
the broad spectrum of available fluorescent proteins allows simultaneous observations of 
different pathways when combining different fluorescent proteins as reporters for different 
biological processes or readouts (e.g. pH, [ATP], [Ca2+]). In contrast to other methods the 
biological material needed is relatively low. When using GEFBs, fluorescent proteins have 
to be chosen carefully considering their fluorescent properties. Validation of results obtained 
with a new biosensor is indispensable since GEFBs can influence cell function and 
properties.  
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3 AIMS 
 
The aims of the thesis were the following: 
1. To establish a technique that allows measurements of β-cell insulin 
sensitivity/resistance longitudinally and non-invasively in vivo.  
2. To investigate β-cell insulin sensitivity/resistance dynamics in different genetic 
mouse models of insulin resistance. 
3. To explore the relevance of β-cell insulin resistance in diet-induced mouse models 
of insulin resistance.  
4. To start the investigation of the consequences of β-cell insulin resistance for β-cell 
function.  
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4 MATERIAL AND METHODS 
 
Cell lines, primary cells, isolated islets of Langerhans as well as mice were used as model 
systems to establish and validate a method to measure β-cell insulin resistance and to study 
β-cell insulin resistance in a defined context. They allowed in a simple and time effective 
way to simulate different situations, e.g. insulin resistance and (pre)diabetes. Using these 
systems in a stepwise and complexity-increasing way, from cell lines to mouse models, 
allowed reflection of achieved results before entering the next level. This was especially 
important when going the step from cell lines to primary cells or islets isolated from animals 
or humans and even more before performing experiments in vivo, to always keep the amount 
of animals to a minimum and only use them when no other system can be used to answer a 
particular question. None of the systems will ever have the ability to represent the human 
situation with its full complexity, but they are useful to test principle ideas and mechanisms 
under certain situations and contribute to a better understanding of underlying regulation.  
4.1 Cell culture 
4.1.1 Cell lines 
4.1.1.1 MIN6m9 cells  
MIN6m9 cells were obtained from Dr. J. Miyazaki69 and share morphological as well as 
functional characteristics with mouse pancreatic β-cells, e.g. insulin secretion in response to 
glucose-stimulation. Therefore they were ideal to investigate molecular mechanisms and to 
test the basic principle and the regulation of the biosensor. MIN6m9 cells were cultured in 
Dulbecco´s modified eagles medium (DMEM) supplemented with final concentrations of 
11 mM glucose, 75 µM mercaptoethanol, 10% heat inactivated fetal bovine serum (FBS) 
and 100 U/ml penicillin and 100 µg/ml streptomycin at 5% CO2 and 37°C.  
4.1.1.2 HEK 293A cells 
Human embryonic kidney (HEK) 293 cells were generated and established by Graham et 
al. by transfection of human embryonic kidney cells in 1977 with shared human adenovirus 
type 5 DNA70. The 293A cell line is a subclone of the 293 cell line that has a relatively flat 
morphology. The genes encoded by the E1 region of adenovirus (E1a and E1b) are 
expressed in these cells and participate in transactivation of some viral promoters, allowing 
these cells to produce very high levels of protein. E1 also complements the E1-deletion in 
recombinant adenoviral vectors, allowing viral replication. In the present thesis HEK 293A 
cells were exclusively used for adenovirus production. They were cultured in DMEM 
without pyruvate supplemented with final concentrations of 25 mM glucose, 10% FBS and 
1% essential amino acids, but without antibiotics at 5% CO2 and 37°C.  
4.1.2 Islets of Langerhans and primary cells 
4.1.2.1 Mouse islets of Langerhans 
Mouse islets were used for in vitro experiments as well as for transplantation to the ACE of 
mice. They were obtained from Umeå-ob/ob (Lepob/ob, ob/ob), ob-control (Lep+/+, ob-
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control), B6 and New Zealand Obese (NZO) mice as described in14. Isolated and handpicked 
islets were cultured in Roswell Park Memorial Institute medium 1640 (RPMI 1640 
medium)71 supplemented with final concentrations of 10% FBS, 2 mM glutamine, 100 U/ml 
penicillin and 100 µg/ml streptomycin at 5% CO2 and 37°C.  
4.1.2.2 Human islets of Langerhans 
Human islets of Langerhans were used to validate findings in the human context. They 
derived from deceased donors and were isolated at the Division of Clinical Immunology at 
the University of Uppsala as described in72. All experiments were approved by the Regional 
Ethical Review Boards in Uppsala and Stockholm. Islets were cultured in complete 
Connaught Medical Research Laboratories (CMRL) 1066 medium supplemented with final 
concentrations of 11 mM nicotinamide, 2 mM L-glutamine, 5 mM sodium pyruvate, 0.25 
µg/ml fungizone, 100 units/ml penicillin G, 100 µg/ml streptomycin-sulfate, 10 mM 
HEPES, pH 7.4 and 10% FBS at 5% CO2 and 37°C.  
4.1.2.3 Primary cells 
To address questions in primary cells, isolated islets were dispersed with Accutase 
(Innovative Call Technologies, Cytotech, Helleback, Denmark), cells were seeded into 96 
well imaging plates and cultured in fully supplemented culture medium.   
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4.2 Fluorescent biosensors- Construction and use 
4.2.1 Fluorescent biosensors  
Fluorescent biosensors allow visualization of cellular processes that are otherwise difficult 
to study (see also Background). Biosensors enable to study certain processes in cells 
expressing them, but it is possible that the biosensor itself influences the cells. Therefore it 
is necessary to validate the results obtained with biosensors with independent methods and 
not exclusively rely on results from biosensors.  
4.2.2 Construction of the β-cell insulin resistance biosensor (βIRB) 
The adenovirus encoding βIRB was generated as follows: pENTR2A.rat insulin promoter 
(RIP)1.FoxO1GFP was generated by replacing the cDNA for EGFP in 
pENTR2A.RIP1.EGFP with that of FoxO1-GFP obtained from pEGFP.N1.hFOXO173. 
IRES-3Tomato was generated by introducing a cDNA encoding three copies of the red 
fluorescent protein dTomato74 downstream of the IRES sequence in pIRES (Clontech, Palo 
Alto, CA, USA). The IRES-3Tomato cassette was then introduced into 
pENTR2A.RIP1.FoxO1GFP thus creating pENTR2A.RIP1.FoxO1GFP-IRES-3Tomato. 
pENTR2A.RIP1.FoxO1(H215R)GFP-IRES-3Tomato was generated by replacing the 
codon for histidine (CAT) 215 by that of arginine (CGT) by site-directed mutagenesis 
employing the QuikChange mutagenesis kit (Stratagene, LaJolla, CA, USA) and respective 
oligonucleotides purchased from Sigma (Paris, France). All constructions were verified by 
DNA sequencing. The expression cassette was transferred into the promoterless adenovirus 
plasmid pAd/PL-DEST (Invitrogen, Carlsbad, CA, USA) by the Gateway technique. The 
ViraPower Adenoviral Expression System (Invitrogen) was used to generate a replication-
deficient adenovirus, which was used for the transduction of cells and islets (paper I). 
4.2.3 Construction of the β-cell fluorescent metabolic transcriptional response 
indicator (βFLUOMETRI) 
The adenovirus encoding βFLUOMETRI was generated as follows: pENTR1A.RIP1. Red 
fluorescent protein (DsRed) 2/rbGK.EGFP/ Cytomegalovirus(CMV).Cerulean was 
generated by inserting the RIP1.DsRed2/rbGK.EGFP-cassette from 
pd2.RIP1.DsRed2/rbGK.EGFP75 into pENTR1A (Invitrogen, Carlsbad, CA, USA) and 
adding a CMV.Cerulean-cassette downstream of the rbGK.EGFP cassette. The three 
individual expression cassettes are separated by transcription blocker sequences from 
pd2EGFP-Promoter (Clontech, Palo Alto, CA, USA). The construct was verified by DNA 
sequencing. The RIP1.DsRed2/rbGK.EGFP/CMV.Cerulean-cassette was transferred into 
the promoterless adenovirus plasmid pAd/PL-DEST (Invitrogen) by the Gateway technique. 
The ViraPower Adenoviral Expression System (Invitrogen) was used to generate a 
replication-deficient adenovirus, which was used for the transduction of islets (paper II). 
4.2.4 Adenoviral transduction of cells and islets 
Cells and islets (human and mouse) were incubated with 107 pfu/ml adenovirus particles 
encoding the biosensor in fully supplemented medium overnight or for 3.5 hours, 
respectively. Thereafter the cells and islets were cultured either until in vitro experiments or 
transplantation (only mouse islets!) were carried out.  
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4.3 In vitro experiments with cells and islets of Langerhans 
4.3.1 Inhibitor treatment 
To investigate the function of a specific protein, the biosensor expressing cells and islets 
were incubated with an inhibitor or a combination of inhibitors for 1 hour and fixed. 
Alternatively they were imaged during the incubation with the inhibitor(s).  
4.3.2 Antibodies and aptamers 
To block the two isoforms of the IR specifically, two blocking antibodies have previously 
been used, a specific antibody against IR-B and an antibody against both IRs (from 
Biodesign). Since these antibodies were no longer available and the little difference of only 
12 amino acids makes the development of specific (custom made) antibodies difficult, a 
new method for specific blocking of the two IR isoforms was necessary. DNA-based 
aptamers, are able to bind their target specifically and inhibit it. The aptamers that 
selectively recognize and block IRs had been synthesized and produced at POSTECH, 
Pohang, Republic of Korea using a modified SELEX procedure76. For antibody/aptamer 
treatment, cells were incubated for 30 min with the respective antibodies/aptamers in cell 
culture medium prior and during the time of EdU incorporation or throughout stimulation 
with insulin. For insulin stimulation, MIN6 cells were stimulated for up to 10 min with 5 
mU/ml insulin in fully supplemented culture medium containing 2 mM glucose.  
4.3.3 siRNA-mediated knockdown 
Another way to investigate protein function is the application of small interfering (si)RNA. 
They recognize the corresponding mRNA and silence it by cleavage. For siRNA-mediated 
knockdown MIN6 cells were first transfected with the siRNA and 48 hours later with other 
expression constructs of interest for some of the experiments. All experiments were performed 
between 96 and 120 hours after transfection with the siRNA. 
4.3.4 Palmitate preparation and treatment 
To simulate a lipotoxic situation, islets were incubated with palmitate. Palmitate was 
prepared by complexing palmitate (Sigma-Aldrich, St.Louis, MO, USA) with 5% free fatty 
acid-free BSA77 and a 0.5% BSA solution was used as control. Transduced islets were 
incubated in a final concentration of 0.5 mM palmitate or 0.5% BSA in serum free, fully 
supplemented medium for up to 144 hours.   
4.3.5 Measurement of proliferation 
Proliferation of cells and islets was measured by using the thymidine analog 5-Ethynyl-2´-
deoxyuridine (EdU) that is incorporated into the DNA of dividing cells. The Click-iT EdU 
Alexa Fluor 488 HCS Assay kit (Invitrogen, Carlsbad, CA, USA) was used to visualize 
EdU-incorporation. In mouse and human primary islet cell preparations, β-cells were 
identified by immunostaining with an insulin C-peptide antibody or insulin antibody.  
4.3.6 Fixation of cells 
For fixation, the cells were grown on coverslips and incubated with 4% Paraformaldehyde 
in Phosphate-buffered saline solution (PBS) and after washing the coverslips were placed 
up-side-down on microscope slides with 20 µl embedding medium (4.8% moviol 
(polyvenyalcohol) and 12% glycerol in Tris HCl-buffer, pH 8.5). Before imaging the 
embedding medium was allowed to dry for at least 12 hours.   
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4.4 Animals models for insulin resistance and in vivo experiments 
4.4.1 Animals 
All animal experiments were performed in accordance with the Karolinska Institutet’s 
guidelines for the care and use of animals in research and were approved by the Institute’s 
Animal Ethics Committee. Animals were cage-housed in the animal core facility at 
Karolinska Hospital at 21°C room temperature at a 12/12 hour day-night-cycle. Before the 
start of the experiment animals were allowed to acclimatize for at least 1 week.  
4.4.1.1 Genetic animal models for insulin resistance 
4.4.1.1.1 ob/ob mice 
The first description of the obese phenotype of mice, that occurred spontaneous in the V 
stock at the Jackson laboratory, is from 195078. Genotyping was not developed by that time, 
but the ob/ob animals could be recognized at an age of 4 to 6 weeks by their body shape. 
Up to 3 months of age they increase rapidly in body weight which further continues on a 
lower level throughout their life. Since then, many studies on ob/ob mice were performed 
to describe and understand their pheno- and genotype more precisely. Batt and Mialhe 
showed in 1966 that the development of the phenotype was due to the increased food intake. 
When food intake was restricted to the amount consumed by normal mice, they did not 
develop high body weight, hyperglycemia and insulin resistance79. The leptin gene could be 
identified as the affected gene, encoding for a hormone that is produced by adipose tissue 
and responsible for lowering of appetite. Since ob/ob mice cannot produce leptin, food 
intake is constantly triggered. Consequently leptin injection could restore normal body 
weight80,81. In 1973 Coleman and Hummel showed the importance of the genetic 
background for the expression of the obese gene in the mouse. The ob/ob mouse is used as 
model of diabetes, obesity and insulin resistance, but is has to be kept in mind that this 
model- as other genetic models as well- is in itself only to a minor extend relevant for the 
human situation where this mutation is rarely found82. 
Leptin deficient ob/ob mice that have been used in the present studies have a C57BL/6J 
background and are originated from Umeå, Sweden. They were inbred in the animal core 
facility at Karolinska Hospital. Discrimination between ob/ob and ob-control littermates 
was achieved by genotype analysis83. The ob/ob mice show transient hyperglycemia, 
hyperlipidemia, hyperinsulinemia, impairment of glucose tolerance, whole-body and β-cell 
insulin resistance, the islets are increased in number and size84,85. The mice improve in some 
of the parameters as they become older and they do not develop a diabetic phenotype in 
contrast to ob-mice bred on the C57 BK/KSJ background86.   
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4.4.1.1.2 NZO mice (NZO/HlLtJ)  
The NZO mice have their origin in the New Zealand Black mouse first described in the 1948 
by M. Bielschowsky87. They are characterized by high body weight, increased body weight 
at weaning age and severe obesity in adulthood88. Impaired glucose tolerance, increased 
insulin resistance, hyperinsulinemia, absent rise in plasma insulin levels upon a glucose 
injection89 and hyperleptinemia90  have been described in NZO mice. Both male and female 
mice have impaired glucose tolerance, but only males develop diabetes (< 50% 
penetrance)90 and this was the reason for us to exclusively work with male NZO mice. They 
have a single point mutation in the gene encoding for the phosphatidlycholine transfer 
protein, giving the genotype: PctpR120H/Pctp+. The mutation leads to a decrease of 
phosphatidlycholine transfer activity and abnormal lipid homeostasis91. In a publication by 
Kluth et al. it was shown that carbohydrate-containing diets increase plasma glucose levels 
in NZO mice. Hyperglycemia leads to dephosphorylating of FoxO1 in the β-cell, which is 
followed by depletion of insulin stores. β-cell loss is triggered by apoptosis and associated 
with a reduction in β-cell specific transcription factors92. In contrast to the ob/ob mice it has 
not been described that NZO mice improve their phenotype by age.  
Male NZO used in the present studies were purchased from Jackson Labs.  
4.4.1.2 Diet-induced animal models for insulin resistance 
To come closer to the human situation were a relation between life style, especially eating 
behavior, weight increase and development of T2DM is seen1, diet-induced  models for 
insulin resistance were employed. For all diet intervention studies B6 mice (Charles River, 
Wilmington, MA, USA, male and female) were used. These mice are most commonly used 
in research, especially for diet intervention studies. B6 mice have been shown to be prone 
to develop metabolic diseases39.The following diets were given to 3 months old B6 mice for 
up to 8 weeks: High Sucrose Diet (HSD): 32% sucrose dissolved in tap water; High Fat Diet 
(HFD): HFD (60% kcal from fat; Harlan TD.06414); High Fat High Sucrose Diet (HFHSD): 
HFD + HSD; High Fructose Diet (HFrD): 32% fructose dissolved in tap water; High Fat 
High Fructose Diet (HFHFrD): HFD + HFrD; Control Diet (Control): Managed formulation 
purified ingredient diet (Lab Diet; #5P76). 
4.4.2 Transplantation of Pancreatic Islets into the ACE 
To investigate β-cell insulin resistance and β-cell function in vivo the in vivo imaging 
platform (see Background) was used. Here, islets are isolated from mice, transduced with a 
virus encoding a fluorescent biosensor and then transplanted to the ACE. The in vivo 
imaging platform is used as a model system to monitor islets of Langerhans in the living 
animal. Since the pancreas can so far not be reached non-invasively with current imaging 
techniques, it is an attempt to come closer to study the pancreatic islet in vivo. Even though 
the islets are situated in the eye of a living animal, it has to be kept in mind that the location 
and environment of the islets are different compared to the islets in the endogenous 
pancreas. Therefore it is necessary to verify results that are obtained by in vivo imaging in 
the eye in the endogenous pancreas. 
Transduced donor islets were 1-3 days after transduction transplanted into the ACE of 
syngeneic, age-matched littermate recipients, using a technique described previously14,13. 
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Mice were anesthetized using isoflurane, then a puncture of the cornea was generated with 
a 27-gauge needle and islets were delivered into the ACE using a glass cannula. Great care 
was taken to avoid bleeding and damage to the iris. After the transplantation, mice were 
injected subcutaneously with Temgesic (0.1 ml/kg; Schering-Plough, Kenilworth, NJ) for 
postoperative analgesia. Before the first imaging islets were let to engraft and vascularize 
for one month. Re-transplantation to the same or the other eye was performed in two-month 
intervals if necessary. 
4.4.3 In vivo measurements and tests in mice 
4.4.3.1 Intraperitoneal Glucose Tolerance Test (IPGTT) 
Glucose tolerance was measured using the IPGTT where the ability of the body to reduce 
blood glucose levels within two hours after glucose administration is determined. Mice 
impaired in glucose tolerance show a more pronounced glucose excursion during the 
tolerance test than normal mice. The test has the advantage that it is easy to perform and 
gives fast indications about dysfunction in glucose handling. The disadvantage is that it is a 
global read-out and not organ-specific.  
Mice were fasted for 6 hours during daytime and 2 g glucose (dissolved in PBS)/kg body 
weight were injected intraperitoneally (i.p.). Glucose levels were determined using the 
Accu-Chek Aviva monitoring system (Roche, Basel, Switzerland) before the glucose 
injection and 5 (not always measured), 10, 30, 60 and 120 min after the injection.  
4.4.3.2 Intraperitoneal Insulin Tolerance Test (IPITT) 
Whole-body insulin resistance was measured employing the IPITT where the ability of the 
whole body to utilize glucose in the presence of provided insulin is measured. Whole-body 
insulin resistant mice do not have the ability to use the insulin for glucose uptake. 
Consequently blood glucose increases more in insulin resistant mice compared to controls 
where a small increase is followed by relatively stable blood glucose values. This test does 
not specifically address any specific tissue, but it excludes the involvement of the β-cell 
since insulin is provided. This experimental setup has the advantage that it is non-invasive 
and that the animals can undergo the test several times during a long-term study, which was 
necessary in the present studies. This is also the reason to use the IPITT instead of the 
euglycemic clamp, where insulin sensitivity of insulin target tissues is measured in a 
terminal experimental approach93.  
Mice were fasted for 6 hours daytime before the basal glucose state (0 min) was measured. 
Then, mice were injected with insulin (0.25 U/kg body weight, diluted in PBS, i.p., Novo 
Nordisk, t = -10 min) followed by glucose administration (1 g/kg body weight, i.p., t = 0 
min) and blood glucose concentrations were determined at 15, 30, 60, 90 and 120 min after 
glucose injection.  
4.4.3.3 Pyruvate Tolerance Test (IPPTT) 
The ability of the liver to utilize pyruvate and to regulate gluconeogenesis was measured by 
employing the IPPTT. For this test, low fasting glucose levels are important to address the 
action of the liver. While normal mice show slightly increased, but otherwise stable blood 
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glucose, liver insulin insensitive mice do no longer have the ability to regulate 
gluconeogenesis, resulting in a substantial blood glucose increase. The IPPTT can only be 
seen in the context of other measurements and tests.  
To achieve sufficient low glucose levels mice were fasted for 12 hours over night and blood 
glucose was measured at basal state (0 min). 2 g pyruvate (dissolved in PBS)/kg body weight 
were injected i.p. and blood glucose levels were determined 30, 60, 90, 120 and 180 min 
after the injection.  
4.4.3.4 Body weight and fasting blood glucose 
Body weight and fasting blood glucose were measured after 6 hours fasting time. 
4.4.3.5 Serum biochemistry 
To analyze factors in the serum, blood samples were obtained at all time points during the 
IPGTT, centrifuged to obtain blood serum and preserved at −20°C until measurement. 
Ultrasensitive mouse enzyme-linked immunosorbent assay (ELISA) kits (CrystalChem, 
Zaandam, Netherlands) were used to analyze different factors in the serum, e.g. C-peptide 
and insulin.  
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4.5 Imaging and image analysis 
4.5.1 In vitro imaging 
4.5.1.1 In vitro imaging of cells 
Either living or fixed cells were imaged using a laser-scanning microscope from Leica 
Microsystems, Germany (Leica TCS SP2). A central plane of each cell was imaged. An 
objective with the following settings was used for detection: Leica HCX PL APO 63x/1.20 
NA. Excitation wavelengths and detection ranges were chosen in respect to the particular 
fluorescent proteins. For more details please see the method section of the corresponding 
paper. 
4.5.1.2 FRET analysis by acceptor photobleaching  
FRET analysis by acceptor photobleaching was used to measure protein/protein 
interactions. The method described by Karpova and McNally was adapted to the Leica TCS-
SP2 confocal microscope94. To determine FRET between IR-B (acceptor) and PI3K-C2α or 
Shc (donors) cells were transfected with constructs encoding mCerulean- or mCyan 
Fluorescent Protein (CFP)- (donor) and mVenus-(acceptor) tagged proteins and fixed before 
the experiment. As illustrated in Fig. 4.1A in total 3 images were obtained with the following 
settings: mCerulean or mCFP: Excitation 458 nm (laser-power 15%), emission detection at 
470-490 nm; mVenus: emission detection at 520-550 nm. Image 1 and 2 were obtained 1 
min part from each other, image 3 was taken after photobleaching of the FRET-acceptor 
mVenus for 1 min by excitation with the 514 nm laser at full power. The values for FRET 
transfer efficiency EF  and control FRET transfer efficiency CF and were calculated using 
the following formulas and having CFP-intensity (CFP) as signal for either mCFP or 
mCerulean: CF=(CFP2 – CFP1)/CFP1; EF=(CFP3–CFP2)/CFP2. All intensities were 
background-corrected before respective calculations. FRET did occur if EF was significantly 
higher than CF, reflecting that photobleaching of the FRET-acceptor mVenus would lead to 
an increased emission of the FRET-donors mCerulean or mCFP (Fig. 4.1B).  
4.5.1.3 In vitro imaging of islets of Langerhans 
Islets were imaged in vitro using a laser-scanning microscope from Leica Microsystems, 
Germany (Leica TCS SP2).  Images were obtained as 3D-stacks with a step-size of 2 µm 
using a Leica HCX PL APO 20x/0.7 NA. Excitation wavelengths and detection ranges were 
chosen in respect to the particular fluorescent proteins. For more details please see the 
method section of the corresponding paper. 
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Fig. 4.1: FRET analysis by acceptor photobleaching 
(A) Donor emission is measured twice (1., 2.) one minute apart from each other and CF is calculated. After 
acceptor bleaching donor emission is measured a third time (3.), used to calculate EF. (B) When EF>CF, FRET 
occurred and both fluorophores are in close proximity to each other.   
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4.5.2 In vivo imaging  
4.5.2.1 In vivo imaging of islets in the ACE 
Transduced and transplanted islets were regularly imaged from 1 month after transplantation 
on14,13. Mice were anesthetized with isoflurane and the islets in the mouse eye were kept in 
a static position during imaging by a custom-built stereotaxic head holder. For the imaging 
Viscotears (Novartis, Basel, Switzerland) was administered as an immersion liquid between 
the eye and the objective. An upright laser scanning confocal microscope (Leica TCS SP5, 
LEICA Microsystems, Wetzlar, Germany) equipped with a long-distance water-dipping 
objective (Leica HXC-APO 10×/0.30 NA) was used. Excitation wavelengths and detection 
ranges were chosen in respect to the particular fluorescent proteins. In addition the 
backscatter signal from the 561 nm excitation was always collected at 555 to 565 nm56. For 
more details, please see the method section of the corresponding paper.  
4.5.2.2 In vivo Ca2+ imaging 
For calcium measurements islets from male B6 mice, heterozygous for InsCRE and floxed 
GCaMP395,96 were isolated and used for transplantation. From 4 weeks after transplantation 
on imaging was performed as follows: 4 hours fasted mice were anesthetized with 
midazolam/fentanyl/fluanison (i.p.) and during the imaging supplied with oxygen via a nose 
mask. The whole microscope was enclosed and heated to 35°C and a 25x/0.95 NA objective 
was used. GCaMP3 was excited with 488 nm and fluorescence was detected at 500-550 nm. 
A tail vein catheter containing 14 µl Heparin (100 IE)/ml was inserted in the mouse´s tail 
and Heparin was injected. 2 minutes after the start of the imaging glucose (0.4 g/kg) was 
carefully injected into the catheter. Images were acquired with μManager over a time of 20 
min after glucose application97.  
4.5.3 Image analysis 
4.5.3.1 Analysis of the β-cell insulin resistance biosensor 
To analyze FoxO1 distribution in the cell, i.e. the insulin sensitivity status of the cell, un-
biased analysis of images obtained by in vitro or in vivo imaging of cells and islets of 
Langerhans was done with the Leica LAS software. Here, the central plane of each cell was 
determined using information from the three detection channels (GFP, Tomato, and 
backscatter). To calculate the ratio of nuclear FoxO1 (FoxO1nuc) to cytoplasmic FoxO1 
(FoxO1cyt), fluorescence intensities of the GFP channel were obtained within three regions 
of interest (nucleus, cytoplasm and background (BG)) that were manually drawn for each 
cell. For each cell a ratio was calculated based on the obtained fluorescence intensity values: 
ratio r = (FoxO1nuc-BG)/(FoxO1cyt-BG). For each experimental in vitro and in vivo condition 
the ratio was calculated. In the first set of experiments (paper I), cells with a ratio r ≥ 1 were 
categorized as insulin resistant and cells with a ratio r < 1 as insulin responsive. Then a 
percentage of insulin resistant cells was calculated and used for statistical analysis.  
Since it was not known whether FoxO1nuc ≥ FoxO1cyt had to be fulfilled for insulin 
resistance and even an increase in the ratio towards more FoxO1nuc could be relevant, in 
following experiments the normalized ratio was used for comparison and statistical analysis 
(paper II). To normalize the ratio a correction value c was used to calculate the relative β-
cell insulin resistance index (rβIRI) for each time point and experimental group: rβIRI = r/c. 
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For in vivo experiments, the mean ratio of the experimental starting time point (t=0) and/or 
control group was used as correction value. More precisely, in the genetic animal studies 
the mean ratio of ob-control mice at 3 months of age was used as correction value. In the 
diet intervention study, the mean ratio of all mice at the time point before the treatment was 
used as correction value. The rβIRI was considered a measure of β-cell insulin resistance 
and used for further statistical analysis. For in vitro experiments, the mean ratio of the 
control group for each individual time point (correction value c) was used to further 
calculate the rβIRI for each time point and experimental group: rβIRI = r/c. All images were 
analyzed using Leica LAS software (Leica Microsystems, Wetzlar, Germany). 
4.5.3.2 Analysis of βFLUORIMETRI 
To calculate the change in fluorescence after glucose stimulation as a readout of β-cell 
functionality, fluorescence intensities for each cell were determined at the beginning of the 
experiment and 4 hours after glucose stimulation. Cells were identified using the DsRed-
fluorescence signal thereby ensuring the analysis of β-cells. Promoter activation was 
calculated as follows:  
((GFP/DsRed240min-Background240min) / (CFP240min-Background240min)) / ((GFP/DsRedStart-
BackgroundStart) / (CFPStart-BackgroundStart)). 
To determine functional β-cell mass as % of glucose responsive cells, cells with a promoter 
activation >1.15 were considered responsive.  
Image analysis for in vitro experiments was performed as described in (35,67,98,99) using 
ImageJ. Average fluorescence intensities for each cell were determined for t = 60 min (start) 
and t = 240 min. 
Images derived from in vivo imaging were analyzed using Leica LAS software (Leica 
Microsystems, Wetzlar, Germany). For each analyzed cell, fluorescence intensity for all 
three fluorescent dyes (CFP, GFP, DsRed) was determined before glucose stimulation and 
240 minutes after glucose stimulation.  
4.5.3.3 Backscatter intensity  
Backscatter intensity was used as indicator for insulin content as described in56 and was 
analyzed in the backscatter images obtained during the imaging of βFLUOMETRI-
biosensor using ImageJ. Average signal intensity of the islet was normalized to average 
signal intensity of the surrounding iris and the ratio was used as backscatter intensity (A.U.).  
4.5.3.4 Islet size 
Islet size was determined based on the backscatter images obtained during the imaging of 
the βFLUOMETRI-biosensor as described in100 using ImageJ. Islet volume was 
extrapolated from maximum projected area and z-depth. Relative islet size was calculated 
by dividing the islet size at 8 weeks by islet size at the start of the experiment for each 
individual islet. 
4.5.3.5 Analysis of calcium imaging 
Image processing was done in Matlab (The MathWorks, USA). Every z-stack was 
denoised101 and consecutive planes were aligned102. Z-stacks were deconvolved103 and 
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registered to a reference z-stack104. Individual β-cells were identified based on their 
temporal [Ca2+]i profile. Single cell [Ca2+]i traces were normalized to their baseline. β-cells 
were considered responding when their glucose induced [Ca2+]i increase was larger than 
three times the standard deviation before glucose injection.  
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4.6 Ex vivo analysis of pancreas tissue and islets of Langerhans 
4.6.1 In situ analysis of pancreas tissue 
4.6.1.1 Pancreas extraction and sectioning 
Pancreas tissue was obtained and sectioned to verify and complement data obtained in vivo. 
Mice were anesthetized with isoflurane and transcardially perfused with PBS followed by 
freshly prepared 4% (wt/vol) paraformaldehyde in PBS. Pancreas were dissected and post-
fixed for 2 hours. Prior to cryopreservation the tissues were processed with a sucrose 
gradient [10-30% (wt/vol) sucrose in PBS containing 0.01% (wt/vol) sodium azide and 
0.02% (wt/vol) bacitracin], then frozen in dry ice and preserved at −80 °C until use. 20 µm 
thick pancreas cryosections were collected on SuperFrost Plus microscope slides (VWR) 
and kept at -20°C until use. 
4.6.1.2 Immunofluorescence in pancreas tissue 
For immunostaining, pancreas tissue cryosections were equilibrated to room temperature, 
washed, blocked and then incubated with the primary antibodies in the presence of 0.1% 
Triton-X100 and 10% FBS at 4°C. After washing, secondary antibodies were applied at 4°C 
and mounting with medium containing DAPI for nuclear counterstaining (Life 
Technologies) was performed after repeated washing. Images were captured using the 
Pathway 855 imaging system (BD Biosciences, San Jose, CA, USA) and analyzed using 
ImageJ. Please see corresponding papers for specific information on used antibodies. 
4.6.1.3 β-cell proliferation measurement with BrdU 
To assess β-cell proliferation in vivo, 0.8 mg/ml of the synthetic nucleoside and thymidine 
analog BrdU (Life Technologies, Carlsbad, CA, USA) was added to the drinking water of 
the mice for one week during the second month of diet intervention. After isolation and 
sectioning, pancreas were stained for BrdU and insulin to determine the amount of 
proliferating β-cells.  
The images were obtained with the Pathway 855 imaging system (BD Biosciences, San 
Jose, CA, USA) and were analyzed with the Cell Profiler (http://cellprofiler.org/). Nuclei 
were identified by 4',6-diamidino-2-phenylindole (DAPI) staining; the intensities of the 
insulin and BrdU staining were measured in nuclear regions and displayed as histogram. 
Insulin positive objects were defined as β-cells. BrdU-positive and –negative cells were 
identified and used for calculation of the percentage of BrdU-positive β-cells and statistical 
analysis. 
4.6.2 In vitro analysis of islets of Langerhans 
4.6.2.1 Immunofluorescence in isolated islets of Langerhans 
Immunofluorescence of pancreatic endogenous FoxO1 localization in isolated islets of 
Langerhans was performed to verify the data from in vivo imaging. Briefly, freshly isolated 
islets were fixed with 4% paraformaldehyde in PBS for at least 48 hours at 4°C. Islets were 
incubated with primary antibodies (anti-FoxO1, anti-insulin) in the presence of 0.5% Triton-
X100 for permeabilization and 10% FBS or 2% of BSA for blocking at 4°C. After removing 
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the primary antibodies and repeated washing with PBS, secondary antibodies were applied 
at 4°C. The islets were imaged by confocal laser scanning microscopy after repeated 
washing. Since collagenase digestion during the islet isolation carries the risk of islet 
damage and the time between islet isolation and staining can change the islet compared to 
the actual in vivo situation, these results were confirmed by in situ immunofluorescence 
staining of pancreas tissue sections that were obtained from pancreas isolated after perfusion 
of the animals. 
4.6.2.2 Western Blotting analysis of islets of Langerhans 
Western blotting was used to specifically quantify proteins and protein phosphorylation. On 
the one hand, it was used to verify the data obtained by in vivo imaging of FoxO1 and on 
the other hand to characterize the status of a β-cell insulin resistant islet cell. Islets were 
lysed immediately after isolation in lysis buffer (50 mM Tris (pH 7.5), 1 mM  EDTA, 1 mM 
EGTA, 0.5 mM Na3VO4, 0.1% (v/v) 2- mercaptoethanol, 1% Triton X-100, 50 mM NaF, 
5 nM sodium pyrophosphate, 10 mM sodium β-glycerol phosphate, 0.1 mM PMSF, 1 μM 
Microcystin, 1 μg/ml of aprotinin, pepstatine and leupeptin each). The proteins (45 μg) were 
separated over a 7.5% SDS-polyacrylamide gel (buffering system according to Laemmli) 
and electrotransferred to Polyvinylidenedifluoride membrane. In case of phospho-specific 
antibodies the membranes were probed first with the respective phospho-specific antibodies, 
then stripped and re-probed with antibodies recognizing the respective total protein levels. 
Please see publications for specific information on used antibodies. Immunoreactivity was 
detected with horseradish peroxidase-conjugated secondary antibodies using Clarity 
Western ECL Substrate and the Chemi Doc Touch Imaging System (BioRad, Hercules, 
California, USA). Band intensities were quantified using Image Lab 5.2.1 software from 
BioRad. 
4.6.2.3 (Co-) Immunoprecipitation 
(Co-) Immunoprecipitation was used for analysis of IR-B and Shc interaction in MIN6m9 
cells as well as interaction of IR-B and Shc or p85 in islets of ob/ob mice.  
Cells were lysed in co-immunoprecipitation lysis buffer (20 mM Tris-HCl pH 8.0, 137 mM 
NaCl, 15% glycerol, 0.5% Triton X-100, 1 mM PMSF, 10 mM NaF, 4 mM Na3VO4, 1 
µg/ml aprotinin, leupeptin and pepstatin each). The lysate was incubated for 30 min at 4°C 
on a rotator, centrifuged (15 min at 12 000 x g) and the supernatant was collected. 1 mg of 
protein was incubated with 5 µg of the immunoprecipitation antibody on a rotator for 16 
hours at 4°C. 50 µl of pre-eliquibrated protein A/G Plus agarose (Santa Cruz Biotechnology, 
USA) were added and incubated for additional 4 hours. Immunoprecipitates were washed 
three times with lysis buffer on ice and then resuspended in 2x SDS sample buffer, boiled 
and separated on a SDS-polyacrylamide gel. Western blot analysis was performed with the 
respective antibodies.  
For the IR-B/Shc interaction experiment MIN6m9 cells were co-transfected with control 
siRNA or siRNA against PI3K-C2α and myc-tagged IR-B. 96 hours after start of 
transfection cells were starved for 6 hours in fully-supplemented culture medium containing 
2 mM glucose. After stimulation with insulin (5 mU/ml) for 10 min cells were lysed. 
Interaction of myc-tagged IR-B with Shc was analyzed with Shc antibody in myc-antibody 
immunoprecipitates.  
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For the co-immunoprecipitation analysis in ob/ob islets, islets from 9-10 mice were pooled 
and disrupted immediately after isolation by treatment with Accutase (Innovative Cell 
Technologies) prior to lysis. IRs were immunoprecipitated and blotted. The membranes 
were probed with the following antibodies: rabbit monoclonal PI3 Kinase p85 antibody, 
rabbit monoclonal IR β antibody or mouse monoclonal IR β antibody, rabbit polyclonal Shc 
antibody (all from Cell Signaling Technology) or mouse monoclonal Shc antibody (BD 
Transduction Laboratories). 
4.6.2.4 Gene expression analysis of islets of Langerhans 
Gene expression analysis of certain genes was used to investigate the molecular 
consequences of β-cell insulin resistance on the β-cell. 100-200 freshly isolated islets were 
processed with RNeasy Mini Kit (Qiagen, Venlo, Netherlands) to isolate RNA. cDNA was 
synthesized using RT2 First Strand Kit and used in a SYBR Green based custom PCR array 
(Qiagen). Analysis was performed as described elsewhere105, where the 2-ΔCT was calculated 
for experimental groups and used for further statistical analysis.  
4.7 Data presentation and statistics 
Origin 2015 64 Bit and Microsoft Office EXCEL were used for statistical analysis. The 
values are expressed as mean ± S.E.M.. The two-sided, unpaired t-test was used to determine 
statistical significance between experimental groups and the two-sided, paired t-test was 
used for comparison within the same experimental group at different time points of the 
study. Data were checked for outliers using Grubbs´ test. Statistical significance was defined 
as follows: *p < 0.05, **p < 0.01 and ***p < 0.001. The data were graphically illustrated 
using Origin 2015 64 Bit.  
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5 RESULTS AND DISCUSSION 
 
5.1 A method to measure β-cell insulin sensitivity/resistance in vivo 
To establish a technique to monitor β-cell insulin sensitivity/resistance in vivo at the single 
cell level longitudinally and non-invasively we used the in vivo imaging platform (see 
Background). To distinguish insulin responsive from insulin resistant β-cells we designed a 
genetically encoded fluorescent biosensor (GEFB) that is expressed in β-cells. Pancreatic 
islets, prior to their transplantation into the ACE, were transduced with an adenovirus 
encoding the biosensor.  
5.1.1 Concept and design of β-cell insulin resistance biosensor (βIRB) 
For the development of the biosensor we took advantage of the ability of the transcription 
factor FoxO1 to change its localization within the cell in response to insulin resistance. 
Under insulin responsive (normal) conditions FoxO1 is phosphorylated by the 
serine/threonine kinase Akt preventing its nuclear import and resulting in cytosolic 
localization. In a situation of insulin resistance, Akt is no longer able to phosphorylate 
FoxO1 which results in FoxO1 shuttling into the nucleus (Fig. 5.1. A) 73,106,107.  
For detection by confocal fluorescent microscopy we fused GFP to FoxO1. To minimize 
the influence of the biosensor on cell function, we mutated the DNA-binding site of FoxO1 
to disallow its DNA binding and avoid its function as a transcription factor, resulting in 
FoxO1(H215R)108. Since the remaining parts of FoxO1 were unchanged, it was comparable 
to endogenous FoxO1. We additionally introduced into the biosensor a triple Tomato cDNA 
(3Tomato) which was separated from the FoxO1-GFP cassette by a virus-derived IRES-
element, allowing co-expression of FoxO1-GFP and 3Tomato. 3Tomato was originally 
intended to be used as a topological and ratiometric reference. It has a total molecular weight 
of 81 kDa and should therefore stay in the cytoplasm and not diffuse into the nucleus, 
because the nuclear pore complex allows passive import of molecules with a maximal size 
of 60 kDa. However, 3Tomato was detectable in the nucleus and had reached the nucleus 
by a yet unknown mechanism. Nevertheless, 3Tomato served for identification of cells 
expressing the biosensor. To ensure β-cell specific expression of the biosensor we choose 
the RIP1 (-410/+1bp) (paper I, fig. 1a). The hypothetical expectation that FoxO1(H215)GFP 
is detectable in the cytoplasm in the insulin-responsive situation and in the nucleus in the 
case of insulin resistance is schematically illustrated in Figure 5.1. B.  
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Figure 5.1: FoxO1 localization under normal and insulin resistance conditions 
(A) If insulin signaling downstream of the insulin receptor is functional, FoxO1 is phosphorylated by Akt and 
stays in the cytoplasm. In case the insulin signaling cascade is non-functional, FoxO1 is no longer 
phosphorylated by Akt and shuttles into the nucleus. The cell is in a state of insulin resistance. (B) Schematic 
illustration of the working principle of βIRB. Adenoviruses encoding βIRB are used to transduce MIN6 cells 
and pancreatic islets. The fluorescent indicator GFP is identified by laser-scanning fluorescent confocal 
microscopy upon excitation with 488 nm. Under normal conditions FoxO1(H215R)GFP (green) is 
cytoplasmic and it shuttles into the nucleus at insulin resistance.  
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5.1.2 βIRB can be used for in vitro assessment of β-cell insulin sensitivity/resistance  
To verify the function and the concept of the biosensor we transduced MIN6 cells and mouse 
islets of Langerhans with adenoviruses encoding βIRB and incubated some of the cells and 
islets with the Akt-inhibitor Akti-1/2, thus mimicking insulin resistance. As shown in paper 
I, fig. 2a, b and 3b FoxO1(H215R)GFP was present in the cytoplasm under normal culture 
conditions and was located in the nucleus when incubated with the Akt inhibitor. In addition, 
we mimicked lipotoxic conditions by incubating mouse and human islets with palmitate. 
Also under these conditions the biosensor indicated insulin resistance (paper I, fig. 3f-k). β-
cell specific expression was tested by immunostaining for insulin in transduced islets of 
Langerhans. As fig. 3a in paper I shows, only β-cells were expressing the biosensor. This 
demonstrated that the biosensor worked as intended. 
5.1.3 βIRB indicates β-cell insulin resistance in insulin receptor and Akt-dependent 
signaling 
Insulin signaling in the β-cell is complex and many different insulin signaling cascades co-
exist (reviewed in 6). It is well accepted that Akt serves as a central player in the metabolic 
branch of insulin signaling. Thus, we defined insulin resistance in the β-cell as any possible 
disturbance in insulin signaling that impairs Akt activity (Fig. 5.1 A). The first step was to 
test the involvement of IRs and/or insulin like growth factor 1 (IGF-1) receptor in the signal 
transduction to βIRB. For that purpose we incubated MIN6 cells and mouse islets of 
Langerhans with HNMPA(AM)3, (100 µM, for 1 hour) an universal IR inhibitor, or the IGF-
1 receptor inhibitor PPP (2.4 µM, for 1 hour). The results revealed that only blocking of IRs 
led to a change in location of FoxO1(HR)GFP, but not the inhibition of the IGF-1 receptor 
(paper I, fig. 2e and 3c-e). This clearly showed that βIRB nuclear exclusion is IR-dependent, 
but not dependent on IGF-1 receptor signaling. These results are in agreement with data 
from IR and IGF-1 receptor KO mice, demonstrating that insulin signaling downstream of 
the IR, but not IGF-1 receptor, is important for FoxO1 nucleus exclusion in the β-cell11.  
In MIN6 cells all three isoforms of Akt, i.e. Akt1-3, are expressed99. We next examined 
which isoform of Akt is responsible for regulation of βIRB. We employed the Akt inhibitors 
1/2 (Akti-1/2) (0.1 to 10 µM, for 1h), inhibiting the three isoforms at different concentrations 
(IC50= 58 nM, 210 nM, and 2.12 µM in vitro for Akt1, Akt2 and Akt3, respectively) and an 
Akt-2 isoform selective inhibitor (Akti-2) (4 µM, for 1h). The results showed that all three 
isoforms convey the signal leading to biosensor location (paper I, fig. 2b-d). Consequently, 
our data confirmed that βIRB reports on β-cell insulin sensitivity that reflects IR/Akt-
dependent signaling. This was further supported by Western blot analysis of islets from 
βIRB-indicated β-cell insulin resistant mice fed a HFHSD for 8 weeks. In these islets 
tyrosine phosphorylation of the IR at Tyr-1150/1151, Akt phosphorylation at Ser-473 and 
FoxO1 phosphorylation at Ser-256 were decreased (paper II, fig. 2c-e).  
5.1.4 βIRB can be used for in vivo assessment of β-cell insulin resistance  
The main goal of generating βIRB was the investigation of β-cell insulin sensitivity in vivo 
by using the in vivo imaging technique (see Background). To test the biosensor in vivo, we 
employed the leptin-deficient ob/ob mouse, because the phenotype of this mouse is well 
characterized. The ob/ob mouse is described as transient hyperglycemic, hyperinsulinemic, 
whole-body and β-cell insulin resistant and shows impaired glucose tolerance at young age 
which improves later in life (see Material and Methods)84,85. βIRB expressing islets were 
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transplanted into the ACE of age-matched littermates. Since ob/ob mice were whole-body 
insulin resistant at young age (3 months) and showed improved insulin sensitivity at older 
age (10 months) (paper I, fig. 4a, b), we chose these two time points to test the biosensor. 
Our results indicated that also the β-cell is insulin resistant at 3 months of age while it is 
insulin responsive at 10 months of age (paper I, fig. 4c, d). To verify these results we isolated 
islets from animals at these respective ages. Immunostaining showed also significantly more 
endogenous FoxO1 in the nuclei of β-cells from young ob/ob mice compared to young ob-
control mice and old ob/ob mice (paper I, fig. 4e, f). Western blot analysis of the 
pFoxO1/FoxO1 ratio confirmed that less FoxO1 is phosphorylated in young compared to 
old ob/ob mice (paper I, fig. 4g). These data demonstrated that the βIRB can be used to 
measure β-cell insulin sensitivity in vivo.  
5.1.5 The fluorescence intensity of the βIRB decreases time-dependently  
The biosensor was intended to be used longitudinally in vivo, however, our data showed that 
the amount of analyzable βIRB-expressing cells decreased with time (paper I, fig. S1). We 
overcame this problem by re-transplanting the mice with freshly isolated and transduced 
islets from littermates or age-matched mice every second month. Thus, we were able to 
monitor the same animal up to 8 months after transplantation, but not the same islets and 
accordingly cells. The decline of analyzable cells was due to a time-dependent reduction in 
fluorescence and independent of imaging (Fig. 5.2). This is most probably due to enforced 
degradation of the biosensor. Since the decline of detectable cells is not universal for all 
adenovirus encoded biosensors (see βFLUOMETRI), the rapid decrease in expression due 
to adenoviral transgene degradation can be disregarded at this point. The whole problem of 
decrease in amount of analyzable cells could be overcome by the generation of a genetically 
modified mouse that expresses FoxO1(HR)GFP in its β-cells. There all β-cells would 
permanently express FoxO1(HR)GFP and the amount of FoxO1(HR)GFP-positive cells 
would be much higher than in islets transduced with the adenovirus. This has successfully 
been shown in GCaMP3-mice (109, S. Jacob et al.; unpublished data).  
 
Figure 5.2: In vitro assessment of the decline of analyzable cells 
Isolated islets were transduced with adenoviruses encoding βIRB and imaged either daily (A) or weekly (B). 
In these islets the amount of analyzable fluorescent cells per islet was determined.    
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5.2 β-cell insulin resistance in genetic mouse models 
5.2.1 β-cell insulin resistance in ob/ob mice changes over time 
We continued to use βIRB in leptin deficient ob/ob mice to investigate the dynamics of β-
cell insulin resistance longitudinally from 3 to 10 months of age. To additionally assess the 
dynamics of the onset of β-cell insulins resistance during month 1 and 2, we needed to 
perform immunostaining of endogenous FoxO1 in isolated islets at these time points, 
because it was technically not possible to transplant mice with biosensor expressing reporter 
islets before the age of 2 months. Since we have previously shown (paper I) that 
immunostaining of endogenous FoxO1 and in vivo imaging of βIRB gave the same results, 
we were confident to combine these two techniques to investigate β-cell insulin resistance 
over time. To minimize the amount of animals, monitoring of βIRB by in vivo imaging was 
the preferred method for this study and used when possible. We combined β-cell insulin 
resistance monitoring with physiological measurements of whole-body and liver insulin 
resistance, glucose tolerance and body weight. The results (Fig. 5.3 A-D) showed that ob/ob 
mice developed β-cell insulin resistance together with whole-body and liver insulin 
resistance as well as impaired glucose tolerance during their second month of life. 
Furthermore, we could demonstrate that β-cell insulin resistance was the first to recover 
before glucose tolerance, whole-body and liver insulin resistance normalized. This approach 
was not sufficient to indicate whether β-cell insulin sensitivity is the cause or the 
consequence of impaired glucose and insulin tolerance, but obviously β-cell insulin 
resistance can improve independently of still present impairment in the other physiological 
parameters.  
Only the body weight remained increased throughout the study, but the strongest body 
weight increase was seen within in the first three months (Fig. 5.3 E). In ob/ob mice β-cell 
insulin resistance was present in a phase of life of rapid and extensive body weight increase, 
where impaired glucose, whole-body and liver insulin tolerance were at their maximum. To 
validate a possible function of β-cell insulin resistance in ob/ob mice during this period of 
life, in-depth analysis of β-cells at this specific time points has to be performed.  
In general these results demonstrated that β-cell insulin resistance can be a temporary state. 
The molecular mechanisms underlying β-cell insulin resistance as well as functional 
consequences should be addressed in the future.   
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Figure 5.3: Dynamics of insulin resistance and other physiological parameters obtained in ob/ob mice  
(A) β-cell insulin resistance: (I) Relative β-cell insulin resistance index calculated from the subcellular 
distribution of endogenous FoxO1 in in situ islets obtained from the pancreas of ob/ob and ob-control mice at 
1 and 2 months of age. (n=4-5 mice) (II) Relative β-cell insulin resistance index of ob-control and ob/ob mice 
from 3 to 10 months of age obtained with βIRB (n=12-15). (B) Whole-body insulin resistance obtained by the 
IPITT and depicted as area under the curve (AUC) of the individual traces obtained during the IPITT (n=3-
12). (C) Liver insulin resistance obtained by the IPPTT and depicted as AUC of the individual traces of the 
IPPTT (n=3-9). (D) Glucose tolerance obtained by the IPGTT and depicted as AUC of the individual traces 
obtained during the IPGTT (n=4-14). (E) Body weight (n=16).  
 (A-E) All studies have been conducted with ob/ob and ob-control mice from 1 to 10 months of age. *p<0.05; 
**p<0.01; ***p < 0.001. Data are expressed as mean ± SEM.   
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5.2.2 β-cell insulin resistance has different dynamics in NZO mice 
To address the question whether insulin resistance dynamics are similar in different mouse 
models, we employed NZO mice (see Material and Methods) to obtain the same 
physiological parameters as in ob/ob mice. These mice have been shown to develop severe 
obesity and T2DM. Furthermore, dephosphorylation of FoxO1 caused by hyperglycemia 
was demonstrated in their β-cells92. Since an appropriate control for NZO mice was not 
available, we used ob/ob and ob-control mice for comparison. As Fig. 5.4 shows, NZO mice 
were both β-cell and whole-body insulin resistant while they did not develop liver insulin 
resistance (Fig. 5.4 A-C). That might be due to the point mutation in the gene encoding for 
the phosphatidylcholine transfer protein leading to abnormal lipid homeostasis and a 
decrease of phosphatidylcholine transfer activity in NZO mice91. This is interesting and 
demonstrates that the development of β-cell insulin resistance is not dependent on the 
presence or parallel development of liver insulin resistance. β-cell insulin resistance in NZO 
mice as, in ob/ob mice, was paralleled by increased body weight and impaired glucose 
tolerance (Fig. 5.4. D, E). In contrast to ob/ob mice, an improvement towards older age 
could not be seen in NZO mice within the actual observation time period.  
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Figure 5.4: Dynamics of insulin resistance and other physiological parameters obtained in NZO mice 
(A) β-cell insulin resistance depicted as relative β-cell insulin resistance index obtained with βIRB (n=3-9). 
(B) Whole-body insulin resistance obtained by the IPITT and depicted as AUC of the individual traces 
obtained during the IPITT (n=5-10). (C) Liver insulin resistance obtained by the IPPTT and depicted as AUC 
of the individual traces of the IPPTT (n=5). (D) Glucose tolerance obtained by the IPGTT and depicted as 
AUC of the individual traces obtained during the IPGTT (n=4). (E) Body weight (n=5).  
 (A-E) All studies have been conducted with NZO, ob/ob and ob-control mice from 3 to 6 months of age. N-
numbers indicated for NZO mice, for n-number of ob/ob and ob-control mice see Fig. 5.3. *p<0.05; **p < 
0.01; ***p < 0.001: NZO vs. ob-control. #p<0.05; ##p<0.01; ###p<0.001: ob/ob vs. ob-control. +p<0.05; 
++p<0.01: NZO vs. ob/ob. Data are expressed as mean ± SEM.   
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The genetic mouse models we used to monitor the dynamics of β-cell insulin resistance have 
the advantage that they had been extensively characterized. We could demonstrate that 
different dynamics for β-cell insulin resistance exist and that β-cell insulin resistance 
developed together with whole-body insulin resistance, impaired glucose tolerance and 
increased body weight, but not necessarily with liver insulin resistance as shown in NZO 
mice. The disadvantage of genetic animal models is the fact that we could not monitor the 
onset of insulin resistance by exclusively using in vivo imaging of reporter islets in the eye 
because of the early establishment of the phenotype. Finally, genetic models poorly 
represent the situation in humans where life style, especially eating behavior, is discussed 
as one of the most important contributing factors in the development of insulin resistance 
and T2DM. 
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5.3  β-cell insulin resistance in diet-induced mouse models 
To investigate the relevance of β-cell insulin resistance under conditions that are more 
relevant to the human situation where eating behavior is thought to affect the development 
of insulin resistance and T2DM1,2, we fed metabolic disease prone B6 mice39 different diets, 
monitored β-cell insulin resistance with βIRB and obtained other physiological parameters. 
Since we kept the genetic background constant, we could correlate the outcomes directly to 
component(s) of the diet. We distinguished between single diets (HSD; HFrD; HFD) and 
combination diets (HFHSD; HFHFrD). A combination diet (i.e. solid food in combination 
with sweetened beverages) probably reflects best the eating behavior in humans in respect 
to fast food consumption. But in general, the transferability of the obtained results and 
interpretation from mouse to human has to be critically considered. Monitoring β-cell 
insulin resistance and other physiological parameters in mice fed one of the different diets 
for 8 weeks revealed that the dynamics of β-cell insulin resistance and other physiological 
parameters are different (paper II; Tab. 5.1).  
 
Table 5.1: Summary of the physiological parameters obtained in male B6 mice fed different diets 
The numbers indicate the week from which on a respective parameter is significantly changed under a certain 
condition. Unchanged parameters are indicated with a minus.  
 
  
 HSD HFrD (Fig.5.5) HFD HFHSD HFHFrD 
β-cell insulin resistance - not measured - 4 - 
Whole-body insulin resistance - - 4 4 1 
Liver insulin resistance - - 4 - 2 
Impaired glucose tolerance - - 1 1 1 
Increased body weight - - 2 4 1 
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β-cell insulin resistance did not develop in animals fed a liquid high sugar diet. Both sucrose 
(paper II, fig. 3) and fructose (Fig. 5.5) feeding in combination with a normal chow diet did 
not provoke any changes in the obtained parameters. Obviously these mice could adapt their 
caloric intake as shown in 110, avoiding weight gain and subsequent impairment of glucose 
and insulin tolerance within the diet intervention period. This is in contrast to the 
observation that fructose provokes overfeeding in humans (reviewed in 111). In B6 mice it 
has been shown before that chow fed mice that were administered fructose- or glucose-
supplemented water were similar in physiological measurements112.  
 
Figure 5.5: Physiological parameters obtained in mice fed a High-Fructose Diet (HFrD) 
(A) Whole-body insulin resistance in HFrD and control diet fed B6 mice at 0 to 8 weeks of treatment obtained 
by intraperitoneal IPITT and depicted as AUC of the IPITT (n=3-6). (B) Liver insulin resistance in HFrD and 
control diet fed B6 mice at 0 to 8 weeks of treatment obtained by intraperitoneal IPPTT and depicted as AUC 
of the IPPTT (n=4-5). (C) Glucose tolerance in HFrD and control diet fed B6 mice at 0, 4 and 8 weeks of 
treatment obtained by intraperitoneal IPGTT and depicted as AUC of the IPGTT (n=6-12). (D) Body weight 
of HFrD and control diet fed B6 mice at 0 to 8 weeks of treatment (n=5-10). Data shown as mean ± SEM, 
*p<0.05, **p<0.01. 
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On the other hand, the administration of a solid diet high in fat led to body weight gain, 
impaired glucose tolerance, whole-body and liver insulin resistance, but not to β-cell insulin 
resistance (paper II, fig. 3). Consequently, lipotoxicity alone was not able to induce β-cell 
insulin resistance within 8 weeks of diet intervention. A HFHFrD also resulted in increased 
body weight, impaired glucose tolerance, whole-body and liver insulin resistance (paper II, 
fig. 1). The effects were more pronounced and developed earlier than during a HFD, but β-
cell insulin resistance did not develop in these animals.  
As shown in paper II, fig. 1 and 2, the combination of a solid diet high in fat and drinking 
water containing sucrose (HFHSD) led to the development of β-cell insulin resistance within 
8 weeks of diet intervention. Sucrose is a disaccharide consisting of fructose and glucose. 
In contrast to fructose, glucose stimulates the production and secretion of insulin by the β-
cell. β-cell insulin resistance was paralleled by whole-body insulin resistance, impaired 
glucose tolerance and increased body weight. In contrast to mice fed one of the other HFDs 
(HFD and HFHFrD) these mice did not become liver insulin resistant. Mice receiving a 
HFHSD might be protected from developing liver insulin resistance due to the glucose 
provided by the sucrose as it has been reported by others before112. There, fructose was 
shown to be associated with increased hepatic fatty acid synthesis and insulin resistance, 
while glucose supplementation led to improved insulin signaling in the liver112. Our results 
show that lipotoxicity and high work-load of the β-cell, provoked by glucose stimulation, 
are necessary for the development of β-cell insulin resistance.  
5.3.1 Female and male mice respond differently to a HFHSD 
In humans, men are more prone to become diabetic than women113,114. Several studies 
demonstrated that the sex hormone estrogen protects against diabetes115. When we fed 
female B6 mice a HFHSD for 8 weeks we also observed a significant increase in body 
weight, impaired glucose tolerance and whole-body insulin resistance (Fig. 5.6 B, D, E). 
The increased body weight and the AUC of the insulin and glucose tolerance tests were 
comparable to those of male mice fed a control diet. As male B6 mice female mice did not 
develop liver insulin resistance (Fig 5.6 C), but in contrast to male mice females did not 
develop β-cell insulin resistance (Fig. 5.6 A). Within in the scope of this thesis work, the 
mechanisms that protect female mice from developing β-cell insulin resistance were not 
further investigated. Others have shown that estrogen is able to improve insulin sensitivity 
and to suppress gluconeogenesis by activation of Estrogen Receptor α-PI3K-Akt-FoxO1 
signaling in the liver116. If this is also true for the β-cell, it could give one explanation for 
the observation that female mice did not develop β-cell insulin resistance. Further research 
will be of importance for the future to obtain deeper insights into the molecular mechanisms 
underlying the effect of diets and sex differences on β-cell insulin sensitivity. 
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Figure 5.6: Dynamics of insulin resistance and other physiological parameters obtained in female B6 
mice fed a HFHSD for 8 weeks 
(A) β-cell insulin resistance depicted as relative β-cell insulin resistance index obtained with βIRB at 8 weeks 
after diet intervention start (n=3-5). (B) Whole-body insulin resistance obtained by the IPITT and depicted as 
AUC of the individual traces obtained during the IPITT before and during a HFHSD intervention (n=4-6). (C) 
Liver insulin resistance obtained by the IPPTT and depicted as AUC of the individual traces of the IPPTT at 
8 weeks after diet intervention start (n=4-6). (D) Glucose tolerance obtained by the IPGTT and depicted as 
AUC of the individual traces obtained during the IPGTT before and during a HFHSD intervention (n=4-6). 
(E) Body weight before and during a HFHSD intervention (n=4-6).  
(A-E) n-numbers indicated for female B6 mice receiving a HFHSD, for n-number male B6 see fig. 1 in paper 
2. *p<0.05; ***p < 0.001: Female B6 mice receiving a HFHSD versus female B6 mice receiving a control 
diet. Data are expressed as mean ± SEM.   
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Taken together we could show that β-cell insulin resistance is also relevant in the context of 
diet-induced whole-body insulin resistance. The divergent effects of the different diets, also 
in respect to sex differences, show the complexity of interactions of genetic and 
environmental factors in the development of T2DM.   
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5.4 Characteristics of β-cell insulin resistance  
Our data have so far demonstrated that β-cell insulin resistance occurs in vivo in genetic 
(ob/ob, NZO) as well as in a diet-induced mouse model of insulin resistance (HFHSD, male 
B6 mice). Next we aimed to understand the consequences of diet-induced β-cell insulin 
resistance and started a characterization of underlying molecular mechanisms. Furthermore 
we investigated a new concept of insulin signaling cascade-selective β-cell insulin 
resistance.  
5.4.1 Diet-induced β-cell insulin resistance is associated with decreased functional β-
cell mass 
Since the HFHSD led to β-cell insulin resistance in male B6 mice, we further used this 
animal diet model for investigating the characteristics of β-cell insulin resistance. 
5.4.1.1 Functional β-cell mass is decreased during diet-induced β-cell insulin resistance 
In order to investigate functional β-cell mass during the development of β-cell insulin 
resistance, we took again advantage of the in vivo imaging platform and a second biosensor, 
the β-cell fluorescent metabolic transcriptional response indicator (βFLUOMETRI) (fig. 4a 
in paper II). βFLUOMETRI is a read-out for integrated β-cell function based on the ability 
of the β-cell to upregulate transcription upon glucose stimulation67. It has been demonstrated 
previously (reviewed in 6) that the whole cascade of events starting with glucose uptake, 
metabolism, insulin secretion and insulin binding to the IR as well as proper insulin 
signaling is necessary for upregulation of the expression of insulin and glucokinase genes 
in β-cells (paper II, fig. S3a). Both the RIP1 as well as the β-cell-active glucokinase 
promoter (bGK) were shown to contain metabolic response elements allowing upregulation 
of promoter activity upon insulin and glucose stimulation in vitro (36,117,118,119; paper II, fig. 
4b). Since we demonstrated that CMV-promoter driven Cerulean was unaffected by insulin 
and glucose stimulation (36; paper II, fig. 4d), we used Cerulean expression for normalization 
(paper II, fig. 4e). So far the concept of glucose-induced promoter activation had only been 
shown and used in vitro. Our in vivo validation of βFLUOMETRI (paper II, fig. 4f; for 
detailed experimental description see paper II, fig. S3b) demonstrated that we could use this 
approach to monitor glucose-dependent promoter activation in vivo. Because the number of 
analyzable cells was relatively high, this biosensor allowed us to determine the mass of 
functional β-cells. To investigate the functional β-cell mass during development and 
presence of β-cell insulin resistance, we transplanted B6 mice with βFLUOMETRI-
expressing reporter islets. One month after transplantation we determined β-cell function as 
well as other physiological parameters and started a HFHSD. Results in paper II, fig. 5a-h 
showed that increased body weight, impaired glucose and insulin tolerance as well as β-cell 
insulin resistance were paralleled by impairment in glucose-stimulated upregulation of 
promoter activity and a decreasing glucose responding β-cells. The relevance of β-cell 
insulin sensitivity for maintenance of β-cell mass has been shown before10, but so far only 
the absolute β-cell mass irrespectively of functionality could be determined120. Here we 
developed, validated and used a method that allowed measurement of functional β-cell mass 
longitudinally in vivo. Our data revealed that β-cell insulin resistance was associated with a 
decline in functional β-cell mass. 
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5.4.1.2 Diet-induced β-cell insulin resistance leads to non-compensatory glucose-
stimulated insulin secretion  
To study the consequences of diet-induced β-cell insulin resistance, we next examined the 
metabolic status of mice fed a HFHSD for 8 weeks. HFHSD-fed mice had higher fasting 
blood glucose as well as higher serum insulin and C-peptide levels compared to mice fed a 
control diet (paper II, fig. 6a,b,e). Also during a glucose tolerance test these mice secreted 
higher amounts of insulin and C-peptide (paper II, fig. 6c,f). In contrast to control mice they 
lacked the ability to further increase secretion upon glucose challenge within the first 5 
minutes of the test (paper II, 6d,g and S4). This was in agreement with the results from β-
cell function measurements using βFLUOMETRI where both RIP1 and bGK promoter 
elements did not respond to the glucose challenge. The backscatter signal of engrafted islets, 
indicative of the insulin content56, was comparable in reporter islets in HFHSD and control 
diet fed mice (paper II, fig. 7c), indicating that β-cells of HFHSD mice did not completely 
deplete their insulin stores in contrast to ob/ob mice. Hence, β-cell insulin resistance 
provoked a relative defect in insulin secretion that did not compensate hyperglycemia. 
Insulin secretion deficiency was also observed in genetic KO mouse models of β-cell insulin 
resistance10,12,38. The differences between diet-induced and KO-induced β-cell insulin 
resistance resulting in relative versus absolute insulin secretion deficiency, respectively, 
might be due to the complete loss of the target protein in the KO model. The diet intervention 
can affect a huge range of proteins in the whole body, but may affect those to a lesser extent, 
thus resulting in less drastic outcome. Nevertheless, the relative defect in insulin secretion 
provoked by β-cell insulin resistance was sufficient to contribute to a diabetes-like 
phenotype.  
5.4.1.3 The defect in glucose-stimulated insulin secretion is downstream of glucose-
stimulated Ca2+ influx 
To study where in the stimulus-secretion coupling the problem occurs that caused the 
inability of the β-cell to respond adequately to a glucose challenge, we measured glucose-
stimulated β-cell Ca2+ excursions in reporter islets in the ACE in vivo. For that purpose, we 
transplanted islets from Ins-Cre:GCaMP3 mice, that express the Ca2+ biosensor GCaMP3 
in β-cells (Jacob et al., unpublished data), to the ACE of male B6 mice. After engraftment 
we fed these mice a HFHSD for 8 weeks. The results showed that Ca2+ excursions and the 
amount of cells that were responding upon a glucose challenge were unchanged in these 
mice (paper II, fig. 7a,b). Consequently the defect in insulin secretion must be downstream 
of glucose-stimulated Ca2+ handling in the β-cells. A failure in insulin exocytosis 
independent from impaired Ca2+ influx was also observed in genetic KO mouse models of 
β-cell insulin resistance12,38.  
5.4.1.4 Syntaxin-1A is, at least in part, responsible for the defect in glucose-stimulated 
insulin secretion during diet-induced β-cell insulin resistance 
To examine the underlying molecular defects causing non-compensatory glucose-
stimulated insulin secretion we performed a biased transcriptomics analysis (qRTPCR) in 
islets from HFHSD and control diet fed mice at 8 weeks of diet intervention (paper II, fig. 
7d). The results showed no gross changes in β-cell identity, because expression of the master 
regulator of β-cell gene expression Pdx1 and the β-cell-specific activator of the insulin gene 
MafA was unchanged. Also expression of genes involved in β-cell glucose handling 
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(GLUT2, glucokinase) was not changed in islets of mice fed a HFHSD for 8 weeks, 
suggesting that glucose metabolism is not defect. Both gene expression analysis and 
Western blot analysis identified the SNARE protein syntaxin-1A to be downregulated 
during β-cell insulin resistance induced by a HFHSD (paper II, fig. 7d,e). The SNARE 
protein syntaxin-1A is a key-protein in insulin exocytosis121,122, which binds both insulin 
granules and L-type voltage gated Ca2+ channels123 to allow glucose-stimulated Ca2+ influx 
close to the release site of insulin. It has been shown before that impaired insulin signaling 
in β-cells results in a decrease in syntaxin-1A expression12,124 and that lipotoxicity reduces 
the association between insulin granules and L-type voltage gated Ca2+ channels leading to 
decreased insulin secretion under conditions of normal glucose-stimulated Ca2+ 
excursions125,126. The decrease in syntaxin-1A provided one explanation for the defective 
glucose-stimulated insulin secretion. Nevertheless, further analysis has to be done to fully 
characterize insulin resistant β-cells.  
5.4.1.5 Diet-induced β-cell insulin resistance is reversible  
In ob/ob mice we observed that β-cell insulin resistance could reverse (5.2.). In order to 
investigate whether dietary-provoked β-cell insulin resistance is also reversible, we fed the 
mice a normal chow diet after 8 weeks of HFHSD diet intervention. As shown in fig. 5, 
paper II mice that once received a HFHSD needed 8 weeks to restore their body weight to 
normal levels. Recovery of glucose tolerance as well as whole-body and β-cell insulin 
tolerance took only 4 weeks. These results clearly showed that β-cell insulin resistance is 
reversible. The recovered β-cell insulin sensitivity was paralleled by improved insulin and 
glucose tolerance. Furthermore, it was accompanied by regain of functional β-cell mass. 
Since β-cells were transduced with βFLUOMETRI prior to transplantation, we can be sure 
that the same β-cells re-gained their function. Recovery from β-cell insulin resistance was 
independent from increased body weight, but occurred when also the body weight 
decreased. A remaining question for the future will be to investigate whether a “point-of-
no-return” exists, i.e. a status of β-cell insulin resistance from which the β-cell is unable to 
recover.   
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5.4.2 Insulin signaling cascade-selective β-cell insulin resistance can lead to a re-
routing of insulin signaling  
A broad variety of insulin signaling pathways exists that form the two major branches, i.e. 
mitogenic and metabolic insulin signaling. In these signaling cascades adaptor proteins act 
as the interphase between the activated IR and the downstream effector proteins. They 
channel the insulin signal to different signaling pathways leading to different biological 
effects127. In the β-cell, the following adaptor proteins have been identified: IR substrate 
(IRS) proteins IRS-1 to IRS-6, Shc, APS, p62dok and Gab-1 and members of the PI3K 
family6. As we define insulin resistance as any possible disturbance in insulin signaling, β-
cell insulin resistance can exist in one specific signaling pathway, while other insulin 
signaling cascades remain intact. The knockdown of the IR-B adaptor protein PI3K-C2α led 
to a higher interaction of IR-B with Shc, resulting in decreased metabolic signaling and 
increased mitogenic signaling, thus re-routing the insulin signal from metabolic to 
mitogenic signaling (paper III; Fig. 5.7).  
5.4.2.1 PI3K-C2α knockdown leads to increased mitogenic insulin signaling and β-cell 
proliferation  
To analyze the consequences of insulin signaling cascade specific β-cell insulin resistance, 
we performed siRNA-mediated knockdown of PI3K-C2α. The IR-B adaptor protein PI3K-
C2α regulates among others the expression of the β-cell glucose sensor glucokinase. The 
lipid product of PI3K-C2α (PI(3,4)P2) leads to activation of Akt which phosphorylates 
downstream members of the insulin signaling cascade such as TBC1D4 and FoxO1. The 
results showed that knockdown of PI3K-C2α led to increased proliferation in MIN6 cells, 
mouse and human primary β-cells (paper III, fig. 1d-f, S1) as well as decreased apoptosis in 
MIN6 cells (paper III, fig. 1g,h, S2). Furthermore we analyzed the phosphorylation status 
of FoxO1 and TSC2 and could show that both proteins were less phosphorylated and thereby 
in an activated state (paper III, fig. S3a,b). These results showed that metabolic insulin 
signaling was decreased. Since proliferation might be associated with mitogenic insulin 
signaling we next analyzed two members of the mitogenic insulin signaling cascade, ERK 
1/2 and c-fos. The results revealed an increase in ERK 1/2 phosphorylation, c-fos promoter 
activity and c-fos protein expression (paper III, fig. 2a-c). Taken together a knockdown of 
PI3K-C2α led to a decrease in metabolic and an increase in mitogenic insulin signaling, 
accompanied by an increase in β-cell proliferation.  
5.4.2.2 PI3K-C2α knockdown leads to a re-routing from metabolic to mitogenic 
pathway via higher interaction of IR-B and Shc 
In order to investigate the mechanism by which the β-cell is able to change from a 
differentiated to a proliferative state by switching from metabolic to mitogenic insulin 
signaling, we first aimed to understand which IR is involved. We employed a pan-antibody 
that blocked both IR isoforms and an antibody that specifically blocks IR-B. Furthermore, 
we used aptamers that allowed specific inhibition of IR-A and -B. Since only blocking of 
IR-B or both IRs, but not blocking of IR-A only, abolished the increase in proliferation after 
PI3K-C2α knockdown of mouse and human β-cells (paper III, fig. 2d-g), we concluded that 
the switch did not occur from IR-B to IR-A signaling, but a re-routing of the signal from a 
metabolic to a mitogenic pathway downstream of IR-B. Furthermore we employed reporter 
gene constructs as read-out for both pathways, i.e. expression of GFP under the control of 
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bGK promoter (metabolic pathway via IR-B/ PI3K-C2α) and DsRed under the c-fos 
promoter (mitogenic pathway via IR-B/Shc/ERK)37,99. PI3K-C2α knockdown resulted in 
increased c-fos promoter-driven DsRed expression while bGK promoter-driven GFP 
expression was decreased (paper III, fig. 2i). It remained to analyze how the β-cell 
mechanistically was able to upregulate signaling via the mitogenic pathway upon PI3K-C2α 
knockdown. To address this question we studied the interaction between IR-B and Shc by 
co-immunoprecipitation and FRET. Both techniques showed a higher association between 
IR-B and Shc when PI3K-C2α was knocked down (paper III, fig. 3a-c). The results 
demonstrated that PI3K-C2α knockdown led to higher interaction of IR-B and Shc which 
re-routed the insulin signal from the metabolic IR-B/PI3K-C2α pathway to signaling via a 
mitogenic pathway involving IR-B/Shc/ERK (Fig. 5.7.). 
5.4.2.3 Re-routing occurs in the diabetic and in vivo context 
Next we wanted to investigate if the above described mechanism can also occur under 
diabetic conditions and in vivo. MIN6 cells were incubated with increasing glucose 
concentrations (2 mM, 11 mM, 25 mM; for 24 hours), mimicking hyperglycemic conditions 
found in diabetes. Figure 3d and e (paper III) show that prolonged elevated glucose levels 
provoked a higher association between IR-B and Shc as well as increased proliferation. 
Since previous studies had shown that ob/ob mice at 3 months of age display an insulin 
resistant phenotype we analyzed protein expression and interaction in islet lysates of 3 
months old ob/ob and control mice with Western blot and immunoprecipitation, 
respectively. The results showed that glucokinase expression was decreased while protein 
levels of c-fos, ERK and Shc were increased (paper III, fig. 4a-g). Furthermore the 
interaction of IR-B with Shc was increased in islets of ob/ob mice compared to control mice 
(paper III, fig. 4h-j). Immunostaining showed that proliferating β-cells, indicated by positive 
KI-67 staining, had lower levels of PI3K-C2α (paper III, fig. S4). Also in mice fed a HFHSD 
for 8 weeks we could observe β-cell proliferation indicated by an increased BrdU 
incorporation in β-cells and an increase in islet size in the ACE (paper II, fig. S6). 
Furthermore we observed a trend towards decreased PI3K-C2α and increased Shc gene 
expression (paper II, fig. 7d). Future work has to explore whether PI3K-C2α protein levels 
are decreased and Shc levels are increased in these animals as well. These results clearly 
demonstrated that re-routing of insulin signaling as the result of selective β-cell insulin 
resistance could be relevant in the diabetic context and in the situation of β-cell insulin 
resistance in vivo.  
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Figure 5.7.: Re-routing of insulin signaling 
PI3K-C2α knockdown leads to higher interaction of IR-B with Shc resulting in a decrease in metabolic 
insulin signaling and an increase in mitogenic signaling associated with increased β-cell proliferation. 
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6  CONCLUSIONS 
 
1. β-cell insulin resistance can be measured non-invasively and longitudinally in vivo 
employing the in vivo imaging platform and the βIRB.  
2. β-cell insulin resistance dynamics vary in different mouse models of insulin 
resistance.  
β-cell insulin resistance develops in the presence of whole-body insulin resistance, 
impaired glucose tolerance and increased body weight, but does not require the 
development of liver insulin resistance. 
3. β-cell insulin resistance is relevant in the context of diet-induced insulin resistance 
and develops in male B6 mice fed a HFHSD.  
4. β-cell insulin resistance in HFHSD-fed male B6 mice is accompanied by decreased 
functional β-cell mass and impaired insulin secretion due to a failure downstream of 
glucose-stimulated Ca2+ influx, in part due to a reduction of syntaxin-1A.  
β-cell insulin resistance in one insulin signaling cascade can lead to re-routing of 
the insulin signal, thus explaining the co-existence of reduced and increased insulin 
responses in the same cell.  
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7 FUTURE PERSPECTIVE 
 
The results of this thesis work show the relevance of β-cell insulin resistance in the context 
of diet-induced insulin resistance. Male B6 mice fed a HFHSD for eight weeks developed 
β-cell insulin resistance due to lipotoxicity induced by the solid diet high in fat (60%) and 
the high β-cell work-load provoked by the drinking water containing a high percentage of 
sucrose (32%). Analysis of the underlying molecular consequences of β-cell insulin 
resistance revealed a defect in glucose-stimulated insulin secretion, which we could track to 
a failure downstream of the glucose-stimulated Ca2+ influx in β-cells. This was, at least in 
part, due to the downregulation of syntaxin-1A gene expression and reduced protein levels 
(paper II). These outcomes were in agreement with previous observations obtained in 
genetically-induced models of β-cell insulin resistance12,38. Employing βIRB had the 
advantage that β-cells could specifically be analyzed non-invasively in the living animal and 
followed longitudinally in vivo (paper I and II). In contrast to that, for gene expression and 
protein analysis whole islets were used, containing all pancreatic islet cell types. Since 50 
to 80% of cells in mouse islets of Langerhans are β-cells20, we are confident that the obtained 
results are relevant and contribute to the understanding of β-cell insulin resistance, but future 
work should aim for single-cell gene expression and protein analysis of insulin resistant β-
cells. This would require labeling of insulin resistant β-cells with β-cell specific makers, e.g. 
Pdx1 or βIRB, followed by sorting, e.g. by fluorescence activated cell sorting (FACS), 
before analysis. In paper III we demonstrated that β-cells that are insulin resistant in one 
signaling pathway can re-route the insulin signal from a metabolic to mitogenic insulin 
signaling pathway. So far, we do not know, if the same β-cells that are insulin resistant, as 
indicated by βIRB, also show re-routing, i.e. a downregulation in PI3K-C2α and 
proliferation. This question could be addressed with the analysis of sorted insulin resistant 
β-cells. In line with the literature on sub-populations of β-cells128–130, also sub-populations 
of insulin resistant β-cells may be identified. This would not be unexpected since several 
insulin signaling pathways act in parallel in the β-cell6 and consequently a defect in insulin 
signaling can occur at different steps within these insulin signaling cascades, leading to 
different β-cell defects.  
Both the genetic predisposition as well as environmental factors have been shown to 
contribute to the risk to develop diabetes26. As we used the same mouse model (male 
C57BL/6J) in the current diet intervention study, we could relate the distinct dynamics of 
insulin resistance and diabetes progression to the particular diets. HFD, HFHSD and 
HFHFrD caused impaired glucose tolerance and whole-body insulin resistance, but only a 
HFHSD provoked β-cell insulin resistance (paper II). By showing that differences in diet-
induced diabetes development exist, probably depending on different underlying molecular 
mechanisms, this study supports the notion of sub-categories of T2DM24. Understanding the 
sub-categories of diabetic patients would allow personalized, specific and especially 
improved treatment regimens for patients.  
Our results demonstrate that β-cell dysfunction occurred early after start of the diet-
intervention, i.e. within 4-8 weeks of diet intervention (paper II). This observation is not 
new131, but stands in contrast to the current view on T2DM development, where it is 
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believed that β-cell failure occurs late as a result of chronic exhaustion. So far, we have 
observed that β-cell insulin resistance was always accompanied by impaired glucose 
tolerance. Blood glucose levels may therefore still be the gold standard for the diagnosis of 
(pre)diabetes, but identification of markers for β-cell insulin resistance is likely to contribute 
to defining sub-categories of diabetic patients and thereby to more specific therapies. 
The results obtained in our studies underscore the relevance and huge impact of diet 
composition as an environmental factor for (pre)diabetes development and the importance 
of prevention programs in terms of life style awareness contributing to a decrease in new 
diabetes cases. Irrespectively of the genetic background, a healthy life style can delay or 
even prevent diabetes progression27,28. WHO and IDF have set the goal to promote a healthy 
life style, including physical activity and a healthy diet1,2. Taken together, personalized 
prevention strategies adapted to the variability in diabetes development and sub-forms 
should be a way to contain the diabetes pandemic. Moreover, people should receive more 
support in everyday life to keep a healthy life style132,133.  
In conclusion, improved methods to study β-cell insulin resistance and its consequences and 
a better understanding of β-cell insulin resistance itself can improve prevention and 
treatment strategies in the struggle against T2DM.  
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